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ABSTRACT
Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of multiple myeloma (MM)
is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the
published medical literature and for grading the quality of the evidence, the strength of the evidence, and the strength of
the treatment recommendations. Treatment recommendations based on the evidence presented in the review were made
unanimously by a panel of MM experts. Recommendations for SCT as an effective therapy for MM include the following:
SCT is preferred to standard chemotherapy as de novo therapy; SCT is preferred as de novo rather than salvage therapy;
autologous peripheral blood stem cell transplantation (PBSCT) is preferred to bone marrow transplantation (BMT); and
melphalan is preferred to melphalan plus total body irradiation as the conditioning regimen for autologous SCT.
Recommendations that SCT is not effective include the following: current purging techniques of bone marrow. Recom-
mendations of equivalence include the following: PBSCT using CD34 selected or unselected stem cells. No recom-
mendation is made for indications or transplantation techniques that have not been adequately studied, including the
following: SCT versus standard chemotherapy as salvage therapy, tandem autologous SCT, autologous or allogeneic SCT
as a high-dose sequential regimen, allogeneic BMT versus PBSCT, a preferred allogeneic myeloablative or non-
myeloablative conditioning regimen, and maintenance therapy post–autologous SCT with interferon alpha post-SCT.
The priority area of needed future research is maintenance therapy posttransplantation with nothing versus interferon
alpha versus other agents such as corticosteroids or thalidomide or its derivatives.
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INTRODUCTION
The American Society for Blood and Marrow Transplanta-
tion (ASBMT) in 1999 began an initiative to sponsor evidence-
based reviews of the scientiﬁc and medical literature for the use
of blood and marrow transplantation in the therapy of selected
diseases. The ﬁrst review of diffuse large cell B-cell non-
Hodgkin’s lymphoma (DLCL) was published in Biology of Blood
and Marrow Transplantation in 2000 [1]. The steering committee
that was convened to oversee the projects invited an indepen-
dent panel of disease-speciﬁc experts to conduct each review.
The following is the second review to result from this
initiative. Its goals are as follows: (1) to assemble and critically
evaluate all of the evidence regarding the role of cytotoxic
therapy with hematopoietic stem cell transplantation (SCT) in
the therapy of multiple myeloma (MM); (2) to make treatment
recommendations based on the available evidence; and (3) to
identify needed areas of research.
The published literature was graded in a systematic manner
on the quality of design (Table 1) and the strength of the
evidence (Table 2). Treatment recommendations subsequently
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were graded based on the quality and strength of the evidence
(Table 3). The treatment recommendations of the expert panel
are detailed in Table 4.
LITERATURE SEARCH METHODOLOGY
PubMed, the web site developed by the National Center of
Biotechnology Information (NCBI) at the National Library of
Medicine of the National Institutes of Health, was searched
using the search terms “multiple myeloma” and “transplant.”
Search results were limited to those studies with human subjects
that were published in the English language between January 1,
1980 and June 1, 2002. In addition, search results were excluded
if they were not peer-reviewed reports or if they were editorials,
letters to the editor, case reports (10 patients), phase I (dose
escalation or dose ﬁnding) studies, reviews, consensus confer-
ence reports, or practice guidelines, or if they did not focus on
an aspect of cytotoxic therapy with SCT for the treatment of
MM (eg, were reports of renal transplantation due to renal
failure in MM patients or otherwise did not focus on an aspect
of cytotoxic therapy with SCT for the treatment of MM).
Abstracts and presentations at national or international meetings
also were not included as evidence in this review due to their
lack of formal peer review, their limited availability of details on
study design and results, and because they usually are presented
as preliminary, not ﬁnal, analyses of clinical trial data.
QUALITATIVE AND QUANTITATIVE GRADING OF THE
EVIDENCE
The hierarchy of evidence, including a grading scheme for
the quality of the evidence, strength of the evidence, and
strength of each treatment recommendation, has been estab-
lished and published as an editorial policy statement in Biology of
Blood and Marrow Transplantation [2]. Tables 1 to 3 are reprinted
from the policy statement and deﬁne criteria used to grade the
studies included in the review and the treatment recommenda-
tions. Study design, including sample size, patient selection
criteria, duration of follow-up, and treatment plan, also was
considered in evaluating the studies. All data in the text and
tables were abstracted from the original articles ﬁrst by one
author (T.H.), then were double checked for accuracy and clar-
ity by another author (P.L.M.) and at least two additional re-
viewers (see Acknowledgments). In some articles there were
discrepancies within the data reported, ie, the median follow-up
reported in the abstract was not the same as the results section
or data presented in a table did not agree with those in the text.
In these cases, the data most consistent with the text of the
article were presented in this review. The ﬁrst author (T.H.)
takes responsibility for any errors that remain. Clinical studies
were summarized with enough detail to give a concise summary
of study design, sample size, eligibility criteria, treatment sched-
ule, duration of follow-up, and outcomes measured. Subjective
statements, such as short versus adequate versus long follow-up,
small versus large sample size, and improper or inappropriate
study design, were not used so that the reader is not biased by
the authors’ opinions.
Appendix A lists the common abbreviations used in this
review. BMT refers to bone marrow transplantation, PBSCT
refers to peripheral blood stem cell transplantation, and SCT
refers to the general term stem cell transplantation including
BMT and/or PBSCT, de novo therapy refers to only one che-
motherapy regimen given before stem cell mobilization and
transplantation, and salvage therapy refers to 2 or more chemo-
therapy regimens given before stem cell mobilization and trans-
plantation.
TREATMENT RECOMMENDATIONS
The strength of this review is the detail conveyed in the text
and the study comparisons in the summary tables at the end of
major sections. Table 4 contains the summary of the treatment
recommendations made by the MM expert panel. Subsequent sec-
tions of the review present the detailed descriptions of the strengths
and weaknesses of the evidence and are speciﬁc to each treatment
recommendation. Additional sections describe other limitations of
this review, SCT costs, MM response criteria, additional ongoing
studies, areas of needed research, and future initiatives.
Table 3. Grading the Strength of the Treatment Recommendation
1 Effective treatment
2 Marginally effective treatment
3 Not an effective treatment
4 Equivalent treatments (no statistical or clinical difference
between therapies)
5 Inadequately evaluated treatment and recommended for
comparative study
6 Inadequately evaluated treatment but not recommended for
comparative study
Republished with permission from Jones et al., Biol Blood Marrow
Transplant 6:524-525, 1999.
Table 1. Grading the Quality of the Evidence
1 Evidence obtained from at least one properly randomized
controlled trial
2-1 Evidence obtained from well-designated, controlled trials
without randomization
2-2 Evidence obtained from well-designated, cohort or case-
controlled analytic studies, preferably from more than one
center or research group
2-3 Evidence obtained from multiple timed series with or without
the intervention, or from dramatic results in uncontrolled
experiments
3 Opinions of respected authorities based on clinical experience,
descriptive studies, or reports of expert committees
4 Evidence inadequate owing to problems of methodology, eg,
sample size, length or comprehensiveness of follow-up, or
conflict in evidence
Republished with permission from Shipp et al. J Clin Oncol 17:423-
429; 1999.
Table 2. Grading the Strength of the Evidence
1 Experimental therapy significantly better (P < .05)
2 Trend in favor of experimental therapy (P > .05)
3 No apparent statistical effect
4 Trend favoring control group (P > .05)
5 Control group significantly better (P < .05)
Republished with permission from Chalmers et al., Stat Med 6:733-
744; 1987.
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TRANSPLANTATION VERSUS CHEMOTHERAPY
Table 5 summarizes the evaluation of the quality and
strength of the evidence, patient characteristics, and outcome
measures for the articles detailed in this section.
De Novo
Attal et al. compared autologous BMT after 4 to 6 alternat-
ing cycles of vincristine, melphalan, cyclophosphamide, and
prednisone (VMCP) and carmustine (BCNU), vincristine,
adriamycin and prednisone (BVAP) (n  100) versus conven-
Table 4. Summary of Treatment Recommendations Made by the Expert Panel for Multiple Myeloma
Indication for SCT
Treatment
Recommendation*
Highest Level
of Evidence† Reference No.‡ Comments
SCT vs. standard chemotherapy as de
novo therapy
1 1 3 Ongoing trials may change the recommendation.
SCT vs. standard chemotherapy as
salvage therapy
5 2 10 There is only 1 non-randomized study that
applies.
SCT as de novo vs. salvage therapy 2 1 13 These are equivalent in terms of overall survival,
however, SCT as de novo is preferred because it
may avoid the inconvenience, cost, and risk of
myelodysplasia from conventional alkylating
agent therapy.
Autologous vs. allogeneic SCT 2 2 17-24 Autologous SCT is recommended over a
myeloablative allogeneic SCT.
Autologous PBSCT vs. BMT 1 2, 3 49-50 PBSCT is preferred based on level 2 evidence
regarding engraftment, not survival, outcomes.
PBSCT is also the accepted standard based on
expert opinion.
Autologous CD34 selected vs.
unselected PBSCT
4 1 51-52
Autologous purged BMT 3 2 65-68
Tandem autologous PBSCT 6 4 A level 1 evidence study has been conducted and
will soon be published to address this critical
question.
Preferred autologous SCT
myeloablative conditioning regimen
1 1 73 Mel is preferred to Mel plus TBI based on toxicity
not efficacy, however, there is no level 1
evidence comparing Mel or Mel plus TBI with
other conditioning regimens (eg, BuCy,
BuMelTt).
Autologous high-dose sequential
regimen
6 4 92-93
Allogeneic BMT vs. PBSCT 6 2 130
Preferred allogeneic SCT
myeloablative conditioning regimen
5 4 131 There is only 1 feasibility study with a small
sample size and no comparison group.
Allogeneic SCT nonmyeloablative
regimen
5 4 132 There is only 1 feasibility study with a small
sample size and no comparison group.
Allogeneic high-dose sequential
regimen
6 No evidence.
Autologous SCT followed by
allogeneic SCT
5 No evidence published. A study is in progress to
address this question.
Maintenance therapy post-autologous
SCT with IFNa vs. none
5 4 138 Early survival advantage (4-5 y) that is lost over
time; problems with study methodology.
Maintenance therapy post-autologous
SCT with IFNa vs. other therapies
(ie, corticosteroids, thalidomide, or
its derivatives)
5 No evidence.
*Deﬁnitions: 1, effective treatment; 2, marginally effective treatment; 3, not an effective treatment; 4, equivalent treatments (no statistical or
clinical difference between therapies); 5, inadequately evaluated treatment and recommended for comparative study; and 6, inadequately evaluated
treatment but not recommended for comparative study.
†Deﬁnitions: 1, evidence obtained from at least one properly randomized controlled trial; 2, evidence obtained from well-designated, controlled
trials without randomization, cohort, or case-controlled analytic studies or multiple timed series with or without the intervention; 3, opinions of
respected authorities based on clinical experience, descriptive studies, or reports of expert committees; and 4, evidence inadequate owing to problems
of methodology, eg, sample size, length or comprehensiveness of follow-up, or conﬂict in evidence.
‡The references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence
described in the review.
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tional chemotherapy consisting of 18 alternating cycles of
VMCP and BVAP (n  100) in newly diagnosed, previously
untreated Durie-Salmon stage II or III MM patients aged
younger than 65 years [3]. The BMT conditioning regimen
consisted of melphalan (MEL) (140 mg/m2) and total body
irradiation (TBI) given in 4 fractions for a total of 8 Gy without
lung shielding. Recombinant interferon alpha (IFNa) was ad-
ministered in 73% of patients in the chemotherapy group start-
ing at cycle 9 until occurrence of relapse (total duration of IFNa
was a median of 12 months), and in 70% of the patients in the
BMT group starting after hematologic reconstitution (total du-
ration of IFNa was a median of 11 months). Patients were
randomly assigned to 1 treatment arm; 74% of the patients in
the BMT group underwent transplantation. Reasons for not
proceeding to BMT were as follows: death (n  5), poor per-
formance status (n  6), abnormal renal function (n  5), and
insufﬁcient amount of bone marrow (BM) collected (n  10).
By intent-to-treat, patients in the BMT group had a signif-
icantly higher response rate (complete or very good partial
response: 90% decrease in the serum paraprotein level) of
38% versus 14% in the chemotherapy group (p  .001). At a
median follow-up measured from the time of randomization of
37 months in the chemotherapy group and 41 months in the
BMT group, the BMT group had signiﬁcantly longer event-free
survival (EFS) (P  .01) and overall survival (OS) (P  .03)
(Figure 1). The rate of treatment-related deaths was 5% in the
chemotherapy group and 7% in the BMT group. Multivariate
analysis of prognostic factors demonstrated that low beta2-mi-
croglobulin (B2M) level and BMT group assignment were sig-
niﬁcantly related to prolonged EFS and only a low level of B2M
was signiﬁcantly related to prolonged OS.
Barlogie et al. performed a phase II study of a planned
tandem transplant regimen as part of “total therapy” consisting
of vincristine, Adriamycin, and dexamethasone (VAD) for 3
cycles, followed by high-dose cyclophosphamide (Cy) and gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF), pe-
ripheral blood stem cell (PBSC), and/or BM collection, 1 cycle
of etoposide, dexamethasone, cytosine arabinoside, and cisplati-
Table 5. Comparison of Patient Characteristics and Outcomes from Articles Included in Transplantation versus Chemotherapy Section
Reference
Quality of
Evidence*
Number
of Patients
in Study
Upper
Age Limit
(Median)
% DS
Stage III TRM
Median
F/U
(mos)
Strength of
Evidence—
OS*
Median
OS (mos)
Strength of
Evidence—
EFS*
Median
EFS
(mos)
De Novo
Attal et al. [3] 1 Chemo 100
BMT 100
Chemo 65
(58 mean)
BMT 65
(57 mean)
Chemo 77%
BMT 72%
Chemo 5%
BMT 7%
Chemo 37
BMT 41
1† Chemo 37.4
BMT NYR
1‡ Chemo 18
BMT 27
Barlogie et al.
[4]
2-2 Chemo 116
SCT 123
70 NS Chemo NS
SCT 4%
31 1‡ Chemo 48
SCT NYR
(62)
1 Chemo 22
SCT 49
Lenhoff et al.
[5]
2-2 Chemo 274
BMT 274
Chemo 60 (54)
PBSCT 60 (51)
Chemo 56%
PBSCT 70%
Chemo NS
PBSCT 4%
Chemo NS
PBSCT 32
1§ Chemo 44
PBSCT NYR
NC Chemo NS
PBSCT 27
Palumbo et
al. [6]
2-2 Chemo 71
BMT 71
Chemo 75
(NS)
PBSCT 75
(NS)
Chemo 72%
PBSCT 75%
Chemo 4%
PBSCT 0%
Chemo 39.4
PBSCT 30
1‡ Chemo 48
PBSCT NYR
(56)
1§ Chemo 17.7
PBSCT 27
Alexanian et
al. [7]
2-2 Chemo 68
SCT 50
Chemo 60 (53)
SCT 60 (49)
NS Chemo NS
SCT 7%
NS 3 NS NC NS
Gianni et al.
[9]
2-2 Chemo 19
SCT 13
Chemo 61 (54)
SCT 59 (50)
Chemo 42%
SCT 92%
Chemo NS
SCT 8%
Chemo NS
SCT 36
1‡ Chemo 14
SCT 41
NC NS
Salvage
Alexanian et
al. [10]
2-2 Chemo 79
SCT 49
Chemo 62
(NS)
SCT 62 (52)
NS Chemo NS
SCT 14%
NS 3 NS NC NS
Mixed Disease
Status—De
Novo and
Salvage
Malpas et al.
[11]
2-2 Chemo 120
BMT 36
All patients 84
(62)
Chemo 84
(NS)
SCT 70 (NS)
71% Chemo 25%
BMT 19.5%
Chemo 63.6
BMT NS
1¶ Chemo 20
BMT 72
NC NS
Gertz et al.
[12]
2-1 67 68 (52) NS NS NS NC 17.2 NC NS
DS indicates Durie-Salmon; TRM, treatment-related mortality; F/U, follow-up; OS, overall survival; EFS, event-free survival; chemo, standard
chemotherapy comparison group; BMT, bone marrow transplantation; NYR, not yet reached; NS, not stated in article; SCT, stem cell transplantation
(bone marrow and/or peripheral blood); PBSCT, peripheral blood stem cell transplantation; NC, no comparison given in article.
*Quality of evidence deﬁnitions are listed in Table 1; strength of evidence deﬁnitions are listed in Table 2; †P  .05 and  .01; ‡P  .01 and 
.001; §P  .001 and  .0001; P  .0001; ¶P  .002 from multivariate, not survival analysis.
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num (EDAP) [4]. Eligible patients were younger than 70 years
of age and had symptomatic MM that was newly diagnosed and
previously untreated. The ﬁrst autologous PBSCT  BMT
conditioning regimen consisted of MEL 200 mg/m2 and the
second autologous PBSCT  BMT conditioning regimen con-
sisted of MEL 200 mg/m2 if  partial response (PR) after the
ﬁrst transplantation, otherwise MEL 140 mg/m2 and TBI in 5 to
6 fractions (850-1020 cGy) were used. IFNa maintenance ther-
apy was administered from hematologic recovery until disease
relapse. One hundred and twenty-three patients were initially
treated with induction therapy; 87% underwent 1 transplanta-
tion and 76% underwent both transplantations a median of 4.5
months apart. Reasons for not undergoing 1 or both transplan-
tations were progression of disease, toxicity of prior therapy, or
patient refusal.
For comparison, a sample of historical patients enrolled in
Southwest Oncology Group (SWOG) trials 8229 (alternating
versus syncopated regimen of VMCP/BVAP) and 8624
(VMCP/BVAP versus VMCPP/BVAPP versus VAD) were pair-
matched to the tandem transplant patients based on age, B2M,
and serum creatinine levels. By intent-to-treat, patients enrolled
in the tandem transplant trial had a signiﬁcantly higher response
rate ( PR) than the pair-matched SWOG trial patients (86%
versus 52%; P  .0001), longer median duration of EFS (49
versus 22 months; P  .0001), and longer median duration of
OS (62 versus 48 months; P  .01) (Figure 2).
Lenhoff et al. compared 348 symptomatic, newly diagnosed,
previously untreated MM patients aged younger than 60 years
treated with high-dose therapy from a prospective population-
based study (274 of whom were treated according to a Nordic
Myeloma Study Group protocol NMSG #5/94) with 313 his-
torical controls aged younger than 60 years selected from 5
previous population-based Nordic studies of conventional ther-
apy (274 of whom fulﬁlled the eligibility criteria for the NMSG
#5/94 protocol and served as the control group) [5]. The authors
estimated, based on population-based incidence studies and can-
cer statistics, that 450 total patients would have been expected in
the prospective high-dose therapy study and 410 total patients
were expected in the historical control group. Therefore, 61%
of the expected incidence of MM patients in the Nordic popu-
lation were included in the prospective study, and 67% were
included in the control group.
NMSG #5/94 consisted of VAD x 3 cycles, PBSC collection
after mobilization with Cy and granulocyte colony-stimulating
factor (G-CSF), PBSCT with MEL 200 mg/m2 as conditioning,
and maintenance IFNa starting 2 months after engraftment
until occurrence of relapse. Autologous PBSCT was completed
in 78% of patients; reasons for not performing autologous PB-
SCT were as follows: allogeneic SCT (n  4), syngeneic SCT
(n 1), early death (n 12), progressive disease (n 11), PR
Figure 2. Superior EFS (top) and OS (bottom) among 116 newly diagnosed patients receiving “total therapy” (TT) compared with 116 closely
matched “pair mates” receiving standard therapy according to SWOG protocols. The median times of follow-up of living patients on TT and SWOG
studies are 31 and 63 months, respectively. Reprinted with permission [4].
Figure 1. Overall survival according to treatment group. The numbers
shown below the time points are probabilities of overall survival (the
percentages of patients surviving) and 95% conﬁdence intervals. Re-
printed with permission [3].
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after induction with VAD x 3 cycles (n  12), contraindications
to high-dose chemotherapy (n 16), and patient refusal (n 4).
The control group consisted of patients from 2 randomized
studies of melphalan plus prednisone (MP) versus MP plus IFNa
and 3 observational incidence studies.
By intent-to-treat, OS was signiﬁcantly longer for the PB-
SCT group compared with the historical control group (median
OS: PBSCT not yet reached, control 44 months; risk ratio for
controls 1.62; 95% conﬁdence interval [CI] 1.22-2.15; P 
.001). After adjustment for differences between the 2 groups
with respect to serum creatinine levels, BM plasma cells, serum
calcium, and serum hemoglobin, the survival advantage per-
sisted. Age, sex, Durie-Salmon stage, M-protein class, osteolytic
bone lesions, serum albumin levels, and platelet count were not
signiﬁcantly associated with OS. Information on performance
status and B2M was available for less than half of controls;
therefore, the effect of these variables on OS was not evaluated
(Figure 3).
Palumbo et al. treated 71 elderly MM patients (aged 55 to
75 years) with 2 to 3 cycles of MEL (100 mg/m2) each followed
by PBSC infusion (treated 1993 to 1997) [6]. Patients who
underwent PBSCT were compared with a sample of 71 patients
(treated 1990 to 1995) matched by age and B2M chosen from a
cohort of symptomatic MM patients treated at diagnosis with
oral MP and who met eligibility criteria for the PBSCT regi-
men. Induction therapy in the PBSCT group consisted of VAD
for 2 to 3 cycles followed by Cy plus G-CSF for mobilization; all
PBSC collections occurred before the ﬁrst course of MEL. By
intent-to-treat, OS and EFS were signiﬁcantly longer for the
PBSCT group. There were no toxic deaths in the PBSCT group
versus 4% in the MP group.
Alexanian et al. compared 68 MM patients who received
autologous BMT or PBSCT within 1 year after the start of
induction chemotherapy with responsive disease (PR or com-
plete response [CR] to induction) with 50 concurrent control
patients with similar disease characteristics and prognostic fac-
tors [7,8]. Control patients were responsive to the same thera-
pies as the group that underwent transplantation and met the
eligibility criteria for intensive therapy but did not receive this
treatment due to patient refusal or denied insurance coverage.
For the SCT group, induction therapy consisted of VAD for2
cycles (n  12), pulse dexamethasone (n  30), high-dose Cy
plus Etoposide plus pulse dexamethasone (n  18) or a combi-
nation of fractionated high-dose Cy with VAD (n  8). Condi-
tioning regimens were MEL (140 mg/m2) plus TBI (850 cGy)
(n  21), thiotepa, busulfan, and Cy (n  40) or thiotepa,
busulfan, Cy, and cyclosporine (n  7). Treatment-related
deaths occurred in 7% of patients who underwent SCT. The
median OS of patients who underwent SCT was 10 months
longer than that of controls (P  .12). Median OS of patients
who converted from PR to CR after SCT was signiﬁcantly
longer (8.3 years) than those who remained in PR after SCT (5.0
years) and the controls with persistent PR after standard therapy
(4.4 years) (P  .03).
Gianni et al. compared 19 historical controls treated accord-
ing to a multicenter randomized study of MEL plus prednisone
or alternating cycles of VMCP/BVAP with 13 patients treated
with a high-dose sequential (HDS) regimen [9]. This HDS
regimen consisted of Cy plus GM-CSF or 1 to 2 cycles of VAD,
followed by vincristine/methotrexate/etoposide, GM-CSF, leu-
kapheresis /- BM harvest, and autologous PBSCT (n  10) or
PBSC plus BMT (n  3) with melphalan (120 mg/m2) plus TBI
(1000 cGy) as the conditioning regimen. Twelve (92%) patients
completed the HDS regimen. Both median freedom from pro-
gression (FFP) and median OS were signiﬁcantly longer in the
patients who were treated with the HDS regimen compared
with the historical chemotherapy-treated controls (FFP: 38 ver-
sus 7 months, P  .0003; OS: 41 versus 14 months, P  .0028).
Salvage
Alexanian et al. studied 49 MM patients who received VAD
plus autologous BMT or PBSCT compared with 79 contempo-
raneous controls who received VAD but did not meet the eli-
gibility criteria for myeloablative therapy due to patient refusal,
denial of insurance coverage, or ineligibility for TBI due to prior
spinal radiotherapy [10]. All patients had been treated with at
least 1 year of therapy prior to VAD or VAD plus transplanta-
tion. Patients who underwent transplantation and controls were
divided into 3 disease response groups: resistant relapse (relaps-
ing despite VAD), primary resistance (resistant to primary ther-
apy for at least 1year), and late remission (in remission after
VAD for treatment of resistant disease). The transplant condi-
tioning regimen consisted of either MEL (140 mg/m2) plus TBI
(850 cGy) (n  26), thiotepa (750 mg/m2) plus busulfan (10
mg/kg) plus Cy (120 mg/kg) (n 18), or thiotepa plus TBI (n
5). In each disease response group, there was no signiﬁcant
difference between the VAD plus transplantation versus the
VAD patients with respect to OS or disease-free survival (DFS).
Mixed Disease Stage (De Novo and Salvage)
Malpas et al. retrospectively compared a cohort of 156
patients treated with conventional chemotherapy or autologous
BMT [11]. The article does not state the median number of
chemotherapy regimens in either patient group. Thus the pro-
portion of patients transplanted as de novo versus salvage ther-
apy is undetermined. One hundred and twenty patients received
MEL (140 mg/m2), MP, or Cy as conventional chemotherapy.
Thirty-six autologous BMT patients received a single agent
conditioning regimen with either MEL (220 mg/m2) or busulfan
(4 mg/kg/d x 4 days). Eleven (31%) of the BMT patients and
Figure 3. Survival for the intensive therapy group and the control
group. The numbers shown below the time points are probabilities of
survival in percent, with 95% conﬁdence intervals in brackets. Reprinted
with permission [5].
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none of the conventional chemotherapy patients received IFNa
maintenance therapy. OS in the BMT group was prolonged
(median 6 years) compared to the conventional chemotherapy
group (median 20 months, P value not stated in original manu-
script). Multivariate analysis showed increasing age (P  .05)
and treatment with conventional chemotherapy (P  .002) were
independent risk factors for shorter OS.
Gertz et al. also reported on 118 MM patients who had
VAD x 4 cycles as either induction or re-induction (after prior
MEL-based chemotherapy) therapy and G-CSF (n  46), G-
CSF plus Cy (n  58), or non-mobilized (n  14) PBSCs
collected and cryopreserved within 6 months of diagnosis [12].
Patients who had primary treatment failure went on to PBSCT
(n  11); all others were treated with vincristine, BCNU, MEL,
cyclophosphamide, and prednisone (VBMCP) maintenance
therapy for 12 cycles and underwent transplantation at ﬁrst sign
of disease progression. A total of 67 patients underwent trans-
plantation (11 early treatment failures and 56 as a result of
progression on or off maintenance therapy) with a median OS
after PBSCT of 17.2 months. Median OS from initial MM
diagnosis of all 118 transplantation and non-transplantation
patients was 58.5 months. There was no comparison of PBSCT
as de novo versus salvage therapy.
TIMING OF TRANSPLANTATION (DE NOVO VERSUS
SALVAGE)
Table 6 summarizes the evaluation of the quality and
strength of the evidence, patient characteristics, and outcome
measures for the articles detailed in this section. Fermand et al.
performed a multicenter prospective randomized trial compar-
ing the optimal timing of autologous PBSCT [13]. After enroll-
ment, all patients received 1 to 2 cycles of intensiﬁed CHOP
(cyclophosphamide 1500 mg/m2, Adriamycin 90 mg/m2, vin-
cristine 1.4 mg/m2, and prednisone; the second cycle also in-
cluded G-CSF) followed by PBSC collection then randomiza-
tion to early versus late PBSCT. The early transplantation
group (n  91) received 3 to 4 cycles of vincristine, adriamycin,
and methylprednisolone (VAMP) followed by autologous PB-
SCT with lomustine (120 mg/m2 day -8), etoposide (250 mg/m2
days -8 to -6), Cy (60 mg/kg day -5), MEL (140 mg/m2 day -4)
and TBI (1200 cGy in 6 fractions days -3 to -1). Patients in the
late transplantation group (n 94) received VMCP as induction
therapy until a stable plateau phase was reached. Once patients
showed either disease progression while receiving VMCP, dis-
ease resistance (no response or PR after 6 courses of VMCP),
or relapse after responding (n 81), they then received monthly
VAMP followed by autologous PBSCT as rescue therapy. IFNa
was used in 56% of remission patients in the early transplanta-
tion group and 60% of remission patients in the late transplan-
tation group. At a median follow-up of 58 months, there was no
signiﬁcant difference in OS, however, there was a signiﬁcant
difference in EFS; the early transplantation group’s median was
39 months (95% CI, 29 to 48) versus the late transplantation
group’s median of 13 months (95% CI, 9.4 to 17.6). The median
time without symptoms, treatment, or treatment toxicity
(TWiSTT) was 27.8 months (95% CI, 23.8 to 31.8) for the early
transplantation group and 22.3 months (95% CI, 16.0 to 28.6)
for the late transplantation group (Figure 4).
Harousseau et al. treated 97 MM patients with one course of
high-dose MEL (120-140 mg/m2) without stem cell rescue [14].
Before this ﬁrst course of high-dose MEL, patients were divided
into 2 groups for analysis: group 1 included 14 primary refrac-
tory and 30 relapsed patients (salvage), group 2 included 53
newly diagnosed untreated patients (de novo). Thirty-ﬁve pa-
tients who achieved a PR or CR to the ﬁrst course of high-dose
MEL (10 from group 1 and 25 from group 2) received an
autologous BMT (n  31) or PBSCT (n  4). Conditioning
regimens were MEL (140 mg/m2; n  18), MEL (140 mg/m2)
plus TBI (1000-1200 cGy) or Cy plus TBI (1000-1200 cGy)
(n  16 for combined MEL plus TBI and Cy plus TBI groups)
or BuCy (n  1). Considering all 97 patients, those in group 2
treated as de novo had a longer median OS from ﬁrst course of
high-dose MEL compared with those in group 1 given high-
dose MEL plus SCT as salvage therapy (37 versus 17 months;
P .16). In the 35 patients who received autologous SCT, there
Table 6. Comparison of Patient Characteristics and Outcomes from Articles Included in Timing of Transplant (De Novo versus Salvage) Section
Reference
Quality of
Evidence*
Number of
Patients in
Study
Upper Age
Limit
(Median)
DS
Stage III TRM
Median
F/U
(mos)
Strength of
Evidence—
OS*
Median
OS (mos)
Strength of
Evidence—
EFS*
Median
EFS
(mos)
Fermand et al. [13] 1 Early 91
Late 94
Early 56
(48 mean)
Late 56
(47 mean)
Early 87%
Late 82%
Early 10%
Late 14%
58 3 Early NYR
(64.6)
Late NYR
(64)
1† Early 39
Late 13
Harousseau et al.
[14]
2-1 De novo 53
Salvage 44
De novo 67
(51)
Salvage 67
(51)
De novo 94%
Salvage 84%
De novo 4%
Salvage 10%
32 3 NS NC NS
Hawkins et al. [15] 2-2 29 63 (56) 63% 17% 28 3 De novo 47‡
Salvage 71
NC NS
Alegre et al. [16] 2-2 259 67 (52) 69% 4% 13 1§ De novo 45
Salvage 28
NC NS
DS indicates Durie-Salmon; TRM, treatment-related mortality; F/U, follow-up; OS, overall survival; EFS, event-free survival; NYR, not yet
reached; NS, not stated in article; NC, no comparison given in article.
*Quality of evidence deﬁnitions are listed in Table 1; strength of evidence deﬁnitions are listed in Table 2; †P  .001 (calculated by authors, P
not stated in article). ‡OS from diagnosis; §P  .05 and  .01.
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was no signiﬁcant difference in OS or progression-free survival
(PFS).
Hawkins et al. reported on 29 MM patients treated with
autologous PBSCT as de novo (n  13) or salvage (n  16)
therapy [15]. Median number of prior chemotherapy cycles
before PBSCT was 7 (range, 0-21). Sixteen patients were re-
sponsive (PR) and 13 were resistant (PR) to debulking che-
motherapy given pre-SCT. De novo patients had a signiﬁcantly
lower treatment-related mortality (TRM) (6% versus 32%; P 
.027), higher CR rate (46% versus 9%; P  .047), and longer
median OS post-PBSCT (33 versus 15 months; P  .01) com-
pared with previously treated patients.
Alegre et al. reported on 259 MM patients from the Spanish
Registry (GETH and PETHEMA) treated with autologous PB-
SCT [16]. Conditioning regimens consisted of MEL (n  96),
MEL plus TBI (n  73), MEL plus busulfan (n  56), busulfan
plus Cy (n  27), and Cy plus TBI (n  7). At the time of
transplantation, patients were in CR (n  56), PR (n  153), no
response (n  25), or progressive disease (n  25). Fifty-two
percent of patients had only one prior chemotherapy regimen
(de novo); 48% had 2 or more prior chemotherapy regimens
(salvage). Multivariate analysis showed the only independent
factors associated with OS and PFS were number of chemother-
apy regimens (1 versus other) prior to autologous PBSCT and
the disease status prior to PBSCT (CR/PR versus other).
AUTOLOGOUS VERSUS ALLOGENEIC SCT
Table 7 summarizes the grading evaluation of the quality
and strength of the evidence, patient characteristics, and out-
comes of the articles reviewed in this section. Lokhorst et al.
prospectively treated 77 newly diagnosed de novo MM patients
with VAD x 2 plus intermediate-dose MEL (IDM) (70 mg/m2)
for 2 cycles (n  62) or IDM for 2 cycles (n  15) as induction
Figure 4. Partitioned Kaplan-Meier survival curves according to treatment group, ie, early HDT group (top) and late HDT group (bottom). Each
plot displays the Kaplan-Meier estimations of time to OS, EFS, and time to end of treatment, either conventional chemotherapy (CCT) or
transplantation (HDT), since randomization. Note that 2 EFS were considered in the late HDT group (after conventional chemotherapy,
“post-CCT,” and after transplantation, “post-HDT”). The areas between these curves and the vertical line at 58 months, which corresponds to the
median follow-up of the whole cohort, represent estimates of the mean durations between these events, namely treatment duration (either CCT [ ]
or HDT []), time without symptoms and treatment toxicity (TWISTT [ ]), and time between relapse and death ( ). All patients were included
in the analysis on an intent-to-treat basis. IFN was not taken into account because it was usually maintained only when well-tolerated. Reprinted with
permission [13].
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therapy [17]. Patients with at least a PR to induction therapy and
an adequate stem cell harvest and who were aged younger than
65 years received autologous PBSCT followed by IFNa main-
tenance (n  50). Those who had at least a PR to induction
therapy, a human leukocyte antigen (HLA)-identical sibling
donor, and were younger than 56 years received an allogeneic
BMT (n  11). The conditioning regimen consisted of Cy plus
TBI for both groups; however autologous PBSCT patients re-
ceived 9 Gy (8 Gy lung dose) in a single dose whereas allogeneic
BMT patients received 12 Gy (8.5 Gy lung dose) in 2 fractions.
Allogeneic BMT patients received a T-cell depleted graft and
cyclosporin A for graft-versus-host disease (GVHD) prophy-
laxis.
Twenty-two percent of patients did not undergo SCT due
to disease progression or no response to induction (n  12),
inadequate stem cell (SC) harvest (n  3), or poor performance
status (n  1). B2M, lactate dehydrogenase (LDH), Durie-
Salmon stage, and performance status were not signiﬁcantly
different between the autologous, allogeneic, and no SCT
groups. There was no statistically signiﬁcant difference in OS
between the autologous and allogeneic transplantation groups
(median OS not yet reached in either group), however, there was
a trend toward improved EFS in the allogeneic BMT group (P
 .078).
Seiden et al. performed a prospective study in MM patients
(including 2 with plasmacytomas) of autologous monoclonal
antibody purged BMT (n  36) or a T-cell depleted allogeneic
BMT (n  21, including 1 syngeneic BMT) if an HLA-com-
patible sibling donor was available [18-20]. All patients had
received a median of 3 prior regimens and were in sensitive
relapse (10% plasma cells in BM) at the time of BMT as
salvage therapy. Conditioning regimens for autologous BMT
patients were MEL (140 mg/m2) plus TBI (1200 cGy; n  20)
or Cy plus TBI (1200-1400 cGy; n  16). Conditioning regi-
mens for allogeneic BMT patients were Cy plus TBI (1400 cGy;
n  19 allografts and 1 syngeneic) or busulfan plus Cy (n  2).
Eighty-one percent of autologous BMT patients were alive at
the median follow-up of 27 months versus 64% of allogeneic
BMT patients alive at a median follow-up of 20 months. Thirty-
nine percent of autologous patients were alive and FFP 18
months post-BMT versus 33% of allogeneic patients alive and
FFP 30 months post-BMT.
Bjorkstrand et al. retrospectively compared 189 allogeneic
BMT patients with HLA-identical sibling donors to 189 auto-
logous PBSCT patients in a matched case control study using
European Group for Blood and Marrow Transplantation
(EBMT) Registry data [21]. Patients were matched on gender
and number of previous chemotherapy regimens. Conditioning
regimens for autologous PBSCT were MEL plus TBI (n  62),
MEL (n  35), MEL plus Cy plus TBI (n  20), MEL plus
other drug combinations (n  39), Cy plus TBI (n  10),
etoposide plus TBI (n  9), busulfan plus Cy (n  9), or other
drug combinations (n  5). Conditioning regimens for alloge-
neic BMT were Cy plus TBI (n  83), busulfan plus Cy (n 
35), MEL plus Cy plus TBI (n  34), Cy plus TBI with MEL
and/or other drugs (n  23), TBI plus drug combinations not
including MEL or Cy (n  9), or busulfan plus Cy plus other
drugs (n  5). Median OS was signiﬁcantly longer in the auto-
logous PBSCT group compared with the allogeneic BMT group
(34 versus 18 months; P  .001), however, after stratiﬁcation by
gender, this survival advantage was observed in men only and
not in women. The survival advantage persisted after correcting
for signiﬁcant differences in the median follow-up times post-
transplantation by selecting 174 allogeneic BMT patients with
their contemporaneous matched autologous PBSCT controls.
Median PFS also was longer in the autologous PBSCT group
(18 versus 10 months), however, at 24 months after transplan-
tation, the PFS curves cross and the statistical signiﬁcance tests
could not be calculated.
Varterasian et al. performed a retrospective multicenter
comparison of autologous unpurged PBSCT (n  24) and allo-
geneic BMT from an HLA-compatible sibling donor (n 24) in
MM patients [22]. The median disease duration for all patients
was 28 months during which all patients had received prior
Table 7. Comparison of Patient Characteristics and Outcomes from Articles Included in Autologous versus Allogeneic SCT Section
Reference
Quality of
Evidence*
Number of
Patients
in Study
Upper
Age Limit
(Median)
DS
Stage
III TRM
Median
F/U
(mos)
Strength of
Evidence—
OS*
Median
OS
(mos)
Strength of
Evidence—
EFS*
Median
EFS
(mos)
Lokhorst et al. [17] 2-1 77 Auto 63 (53)
Allo 55 (43)
81% (all
patients)
Auto 4%
Allo 18%
44 (all
patients)
3 Auto NYR
Allo NYR
2 Auto 40
Allo NYR
Seiden et al. [18] 2-1 Auto 36
Allo 22
Auto 65 (48)
Allo 56 (44)
66% (all
patients)
Auto 3%
Allo 9%
Auto 27
Allo 20
NC Auto NYR
Allo NS
NC NS
Bjorkstrand et al.
[21]
2-2 Auto 189
Allo 189
Auto 65 (49)
Allo 60 (43)
Auto 67%
Allo 65%
Auto 13%
Allo 41%a
Auto 30
Allo 46
1† Auto 34
Allo 18
NC NS
Varterasian et al.
[22]
2-2 Auto 24
Allo 24
Auto 64 (55)
Allo 56 (43)
Auto 21%
Allo 18%
Auto 12.5%
Allo 25%
Auto 11
Allo 15
3 Auto 33.5
Allo 38.6
3 Auto 16.7
Allo 31
Reynolds et al. [23] 2-2 Auto 35
Allo 21
Auto 68 (55)
Allo 56 (48)‡
NS Auto 6%
Allo 19%
Auto 15.4
Allo 27.5
3 Auto NYR
Allo NYR
NC NS
Couban et al. [24] 2-2 Auto 40
Allo 22
Auto 57 (45.5)
Allo 53 (43)
Auto 62%
Allo 50%
Auto 5%
Allo 27%
Auto 15
Allo 42
1§ Auto NYR
(48)
Allo 7
NC NS
DS indicates Durie-Salmon; TRM, treatment-related mortality; F/U, follow-up; OS, overall survival; EFS, event-free survival; auto, autologous
SCT; allo, allogeneic SCT; NYR, not yet reached; NC, no comparison given.
*Quality of evidence deﬁnitions are listed in Table 1; strength of evidence deﬁnitions are listed in Table 2; †P  .001 and .0001; ‡P  .01 and 
.001; §P  .05 and  .01.
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therapy with conventional MM regimens with varied disease
responses. Conditioning regimens for autologous PBSCT pa-
tients were MEL (140 mg/m2) plus TBI (n  23) or MEL (200
mg/m2) (n  1) and 1 of the following 4 combinations for
allogeneic BMT patients: Cy plus TBI (1200 cGy) (n  15),
busulfan plus Cy plus total marrow irradiation (TMI) (n  5),
cyclophosphamide, etoposide, BCNU (CVB) (n  3), or MEL
(140 mg/m2) plus TBI (n  1). At a median follow-up of 11
months for the autologous and 15 months for the allogeneic
transplantation patients, there was no signiﬁcant difference in
median OS (33.5 versus 38.6 months; P .7637) or median EFS
(16.7 versus 31 months; P  .8450).
Reynolds et al. performed a retrospective single center com-
parison of 35 autologous PBSCT patients with 21 historical
allogeneic BMT (n  6) or PBSCT (n  15) patients with
HLA-identical (n 20) or 1 antigen mismatched (n 1) related
donors; both autologous and allogeneic SCT patients were
given an identical conditioning regimen: busulfan plus Cy plus
TBI (900 cGy) [23]. Before SCT, patients were treated with at
least 1 cytoreductive regimen until best response; median time
from diagnosis to SCT was 238 days in the autologous group
and 276 days in the allogeneic group (P  .75). The Kaplan-
Meier probability of disease progression was 11% in the allo-
geneic group and 64% in the autologous group (p  .001).
Two-year PFS (60% versus 30%; P  .19) and 2-year OS (60%
versus 42%; P  .39) were higher in the allogeneic group but
were not statistically signiﬁcantly different. TRM was higher in
the allogeneic group but not signiﬁcantly different than the
autologous group.
Couban et al. retrospectively compared a cohort of 40 au-
tologous PBSCT and 24 allogeneic (including 2 syngeneic)
BMT or PBSCT patients transplanted for MM at a single center
[24]. All allogeneic transplant recipients had related HLA-
matched (6/6) donors. All patients had 1 to 4 chemotherapy
regimens before transplantation and underwent transplantation
as de novo or salvage therapy. Patients treated with autologous
versus allogeneic transplants had comparable disease status at
time of transplantation. Conditioning regimens for autologous
transplants were MEL (160 mg/m2), TBI (1200 cGy), and eto-
poside (n 29), busulfan plus Cy (n 8), or MEL (160 mg/m2)
plus TBI (500 cGy in a single fraction) (n  3). Conditioning
regimens for allogeneic transplants were Cy plus TBI (1200
cGy) (n  14), busulfan plus Cy (n  9), or MEL (160 mg/m2)
plus TBI (1200 cGy in 6 fractions) (n  1). Three-year PFS was
not statistically signiﬁcantly different between autologous (17%;
95% CI, 0-36.6) and allogeneic (22%; 95% CI, 4-39.6) trans-
plants. Three-year OS was signiﬁcantly higher in autologous
(74%; 95% CI, 52.4-95.6) versus allogeneic (32%; 95% CI,
12.4-51.6) transplant patients.
AUTOLOGOUS SCT
Several studies have demonstrated the feasibility, safety, and
efﬁcacy of PBSCT and/or BMT with MEL-based conditioning
regimens in previously untreated, newly diagnosed MM patients
[25-28], as salvage therapy for relapsed or refractory disease
[29-35], and in MM patient populations with mixed disease
responses to prior therapy [36-41]. Three studies demonstrated
the safety and efﬁcacy of autologous transplantation: 1 study in
17 MM patients aged older than 65 years [42], 1 study in 70
patients aged 70 years or older [43], and 1 study in 10 patients
with active ongoing respiratory syncytial virus (RSV) infection
[44], and 4 studies have been completed for patients in renal
failure (total 99 patients, 48 of whom were on chronic hemodi-
alysis) [45-48].
Autologous Peripheral Blood versus BMT
Raje et al. compared two sequential phase II studies: the ﬁrst
of patients receiving autologous BMT (n  26), the second of
individuals treated with autologous PBSCT (n  37) [49]. Me-
dian age was 50 years for BMT patients and 49 years for PBSCT
patients. Seventy-three percent of BMT and 76% of PBSCT
patients had stage III disease. All patients received induction
therapy with Cy, vincristine, adriamycin, and methylpred-
nisolone (C-VAMP), conditioning regimen of MEL (200 mg/
m2), and IFNa maintenance therapy posttransplantation. PBSCs
were mobilized with G-CSF alone. Median follow-up of both
groups was 30 months. The two groups showed no signiﬁcant
differences in known prognostic factors, including age, gender,
disease stage, performance status, serum creatinine level, or
B2M. PBSCT patients recovered platelets signiﬁcantly faster
than BMT patients (19 versus 33 days; P  .0015), however,
there were no signiﬁcant differences between the groups with
regard to neutrophil engraftment, OS, or PFS.
Harousseau et al. retrospectively compared 81 autologous
BMT patients with 51 autologous PBSCT patients from 18
French centers who were treated during a 7-year period [50].
The median ages were 55 years for BMT and 49 years for
PBSCT patients. Stage III disease was present in 86% of BMT
and 80% of PBSCT patients. Signiﬁcant differences between
the 2 patient groups were found for age (PBSCT 49 years versus
BMT 55 years, P  .001), duration of prior chemotherapy,
interval between stem cell collection and transplantation, and
conditioning regimen (more TBI-containing regimens and
higher doses of irradiation in the PBSCT group). Overall me-
dian follow-up was 35 months. There was no signiﬁcant differ-
ence between the PBSCT and BMT groups regarding CR rate,
overall response rate, OS, EFS, or relapse-free survival (RFS). A
subgroup analysis matching 43 PBSCT and 43 BMT patients
for age and disease status at time of transplantation also showed
no signiﬁcant difference between the two groups regarding
median OS (BMT 31 versus PBSCT 45 months), median EFS
(BMT 18 versus PBSCT 22 months), or median RFS (BMT 33
versus PBSCT 36 months). PBSCT patients had a signiﬁcantly
shorter time to neutrophil engraftment but no signiﬁcant dif-
ference in platelet recovery compared with BMT patients.
Autologous CD34 Selected versus Unselected
PBSCT
Table 8 summarizes the evaluation of the quality and
strength of the evidence, patient characteristics, and outcomes
of the articles reviewed in this section.
Stewart et al. performed a multicenter randomized phase III
trial of CD34 selected (n 93) versus unselected PBSCT (n
97) for the treatment of MM [51,52]. Although CD34 selec-
tion signiﬁcantly reduced the tumor burden in the stem cell
products measured as the identiﬁcation of a clonal immunoglob-
ulin (Ig) sequence by a median of 3.1 logs [51], there was no
difference in the median PFS (100 versus 104 weeks; P  .82)
(Figure 5) or median OS (202 weeks versus not yet reached; P
.784) between the CD34 selected versus unselected treatment
arms [52]. There also was no signiﬁcant difference in the median
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time to neutrophil engraftment between the CD34 selected
versus unselected groups. There was a trend toward a signiﬁ-
cantly slower platelet recovery in the selected arm (at day 100,
15% versus 26% had platelet recovery; P  .052).
Several feasibility studies of CD34 selection of PBSC
harvests previously had demonstrated its ability to reduce the
tumor burden in the products without adversely affecting en-
graftment kinetics [53-58]. One study demonstrated the feasi-
bility of performing CD34 selection on the products from
multiple cycles of stem cell mobilization and collection [59].
Two studies compared CD34 selected versus unselected
autologous PBSCT patients in prospective, non-randomized
clinical trials and found no signiﬁcant differences in neutrophil
or platelet recovery between the 2 groups [60,61]. One study
Table 8. Comparison of Patient Characteristics and Outcomes from Articles Included in the Autologous CD34 Selected versus Unselected PBSCT Section
Reference
Quality
of
Evidence
Number
of Patients
in Study
Upper
Age Limit
(median)
D-S
Stage III TRM
Median
Follow-Up
(mos)
Strength
of
Evidence*
Median d
to ANC >
500/mm3
Strength
of
Evidence†
Median d
to Platelets >
20,000/mm3
Stewart et al.
[51]
1 Sel 93
Unsel 97
Sel 70 (51)
Unsel 68 (53)
NS NS 37 3 NS 3 NS
Abonour et al.
[53]
2-1 18 65 (53) 44% NS 25 NC 11 NC 15
Lemoli et al.
[54]
2-1 23 55 (47.5) 59% NS 12 3 Sel 10
Unsel 10
3 Sel 11
Unsel 15
Schiller et al.
[57]
2-1 55 69 (52) 55% 11% 33 NC 12 NC 12
Dyson et al. [59] 2-1 34 65 (51) NS NS NS NC NS NC NS
Patriarca et al.
[60]
2-1 Sel 23
Unsel 16
Sel 63 (54)
Unsel 62 (55)
Sel 65%
Unsel 63%
NS 18 3 Sel 12
Unsel 12
3 Sel 21
Unsel 16
Gupta et al. [61] 2-1 Sel 20
Unsel 16
Sel 62 (NS)
Unsel 64 (NS)
NS 0% 23 3 Sel 14
Unsel 14
3 Sel 14
Unsel 13
Michallet et al.
[62]
2-1 23 65 (55) 77% 9% 15 1 Higher Dose‡
10
Lower Dose‡
12
1 Higher Dose
13
Lower Dose
64
Lemoli et al.
[63]
2-1 Single 35
Tandem 47
Single 64 (51)
Tandem 60
(52)
Single 69%
Tandem 66%
4% Single 34
Tandem 28
Single 3
Tandem 3
NC Single 3
Tandem 3
NC
Gandhi et al.
[64]
2-2 Sel 15
Unsel 15
Sel 64 (53)
Unsel 63 (55)
Sel 67%
Unsel 60%
Sel 13%
Unsel 7%
Sel 32
Unsel 57
1§ Sel 14
Unsel 11
1§ Sel 23
Unsel 14
DS indicates Durie-Salmon Stage; TRM, treatment-related mortality; ANC, absolute neutrophil count; NS, not stated in original article; NC, not
compared in original article; Sel: CD34 Selected, Unsel: CD34 Unselected.
*Strength of evidence comparing neutrophil engraftment; †strength of evidence comparing platelet engraftment; ‡higher dose: CD34Thy1
0.8  106 cells/kg, lower dose: CD34Thy1 0.8  106 cells/kg. §, P  .05 and  .01.
Figure 5. Kaplan-Meier probability of progression-free survival of 188 patients on an intent-to-treat basis. Reprinted with permission [51].
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demonstrated that all patients who received a high cell dose of
0.8 x 106 CD34Thy1 cells/kg had signiﬁcantly faster neu-
trophil engraftment (median 10 days versus 12 days; P  .003)
and platelet recovery (median 13 days versus 64 days; P  .008)
than those who received a low cell dose of 0.8 x 106
CD34Thy1 cells/kg [62].
One study compared single versus tandem CD34 selected
PBSCT in a non-randomized prospective trial [63]. There was
no difference in platelet or neutrophil recovery in single or
tandem SCT when comparing CD34 selected versus un-
selected PBSCT. One case-control study showed a signiﬁcantly
longer time to neutrophil and platelet recoveries in CD34
selected PBSCT patients but no difference in PFS or OS [64].
Autologous Purged versus Unpurged SCT
Reece et al. reported the feasibility of BMT in 14 patients
with marrow purged ex vivo with 4-hydroperoxycyclophospha-
mide [65]. Forty-three patients underwent evaluation at diagno-
sis of MM, 24 of whom received VAD for induction therapy.
Seventeen patients were eligible for BMT based on adequate
disease response, 16 of whom underwent harvesting. Two pa-
tients who underwent harvesting showed high (40%) percent-
ages of plasma cells in their harvests, leaving 14 patients with a
median of 3% plasma cells (range, 1%-7%) before purging who
underwent transplantation with purged BM. All patients
achieved neutrophil engraftment a median 19 days post-BMT
and the last platelet transfusion was given a median 32 days
post-BMT. Four of the 14 BMT patients were alive and pro-
gression-free a median 20 months after BMT.
Lemoli et al. described the feasibility of PBSCT with
CD34 selected products followed by negative selection using
ex vivo immunomagnetic depletion to purge CD10, CD19,
CD20, and CD56 (B-lin) cells [66]. Fourteen patients were
mobilized with Cy plus G-CSF, 2 of whom did not mobilize
adequate CD34 cells and were infused with unmanipulated
PBSC. Therefore, 12 patients underwent transplantation with
CD34 B-lin- cells after conditioning with MEL (200 mg/m2).
Median time from diagnosis to PBSCT was 45 months (range,
5 to 144 months). All patients engrafted neutrophils a median 12
days (range, 6 to 24 days) and platelets a median 14 days (range,
11 to 25 days) post-PBSCT. At a median follow-up of 14
months, 11 patients were alive, 4 of whom were in continuous
CR and 3 had stable disease.
Rasmussen et al. studied the feasibility of PBSCT with
CD34 selected products followed by CD19 depletion in 14
previously untreated MM patients [67]. All patients received
VAD x 3 cycles, G-CSF or Cy (4 g/m2) plus G-CSF, leuka-
pheresis, ex vivo manipulation (CD34 selection followed by
CD19 depletion with murine antibody), and PBSCT with MEL
(200 mg/m2) conditioning. All patients engrafted neutrophils
at a median of 11 days (range, 10 to 17 days) and platelets at
a median of 12 days (range, 11 to 18 days) post-PBSCT. No
patient died of TRM within 100 days post-PBSCT. At a median
follow-up of 26 months (range, 7 to 35 months), 13 patients
were alive, 3 in continuous CR, 9 in PR, and 1 with stable
disease.
Barbui et al. randomized 60 newly diagnosed symptomatic
MM patients to receive either unmanipulated (n  31) or
purged (n  29) tandem PBSCT [68]. All patients were previ-
ously untreated and received VAD x 3 cycles, Cy (7 g/m2) plus
G-CSF for stem cell mobilization, randomization to purged
versus unpurged PBSCT, leukapheresis, ﬁrst PBSCT with MEL
(200 mg/m2), and 3 to 6 months later a second PBSCT with
either MEL (200 mg/m2) or MEL (140 mg/m2) plus TBI.
Adequate PBSCs were collected to perform two transplantations
(target cell dose of 4 x 106 CD34 cells/kg for each PBSCT).
Patients randomized to the purged arm had unmanipulated
PBSCs stored as back-up. Purging was performed using mono-
clonal antibodies against CD19, CD56, and CD138.
Eighty-six percent of patients in the purged and 87% in the
unpurged treatment arm completed both transplantations.
There was no difference in the time to neutrophil or platelet
recovery, discharge from hospital, or transfusion requirements
between the purged and unpurged PBSCTs. No patients in
either group died of TRM. At the time of the ﬁrst PBSCT, 23%
of purged PBSCT patients and 48% of unpurged PBSCT pa-
tients were in CR. At a median follow-up of 23 months, the
3-year EFS rate was 72% in the purged and 40% in the un-
purged PBSCT group (P  .05). The 3-year OS rate was 83%
for the purged and 83% for the unpurged PBSCT groups. By
multivariate analysis, factors associated with prolonged EFS
were B2M 3 mg/L (P  .04), purged PBSCT (P  .03), and
in CR at time of ﬁrst PBSCT (P  .006).
Autologous Tandem versus Single SCT
Table 9 summarizes the evaluation of the quality and
strength of the evidence, patient characteristics, and outcomes
of the articles reviewed in this section.
Barlogie et al. compared tandem transplantations versus
standard chemotherapy without stem cell support, which has
been previously detailed in this review [4]. Additional patients
were accrued in the tandem transplantation regimen (“total
therapy”) and follow-up of the original patients was updated
[69]. This updated study reported on 231 patients, of whom
88% completed induction therapy, 84% completed the ﬁrst
transplantation, and 71% completed the second. Fourteen pa-
tients received their second planned transplantation from an
HLA-matched allogeneic donor. By intent-to-treat, 5-year OS
and EFS rates were 58% and 42%, respectively. Statistically
signiﬁcant prognostic factors for prolonged OS and EFS by
multivariate analysis were the absence of unfavorable cytogenet-
ics (11q breakpoints and/or partial or complete deletions of
chromosome 13) and low B2M.
Vesole et al. compared patients with advanced and refrac-
tory MM who received MEL (90-100 mg/m2) with no stem cell
rescue (MEL100) (n  47) versus MEL (140 mg/m2) plus TBI
or thiotepa plus TBI and autologous BMT (MEL140) (n  21)
versus MEL (200 mg/m2) with autologous BM plus PBSCT as
a tandem transplantation (MEL200) (n  67) [70]. Patients in
the MEL200 group had signiﬁcantly more favorable prognostic
factors (lower incidence of elevated LDH and B2M, resistant
relapse, and 12 months of prior therapy) than either the
MEL100 and MEL140 groups. A multivariate regression anal-
ysis of favorable factors for EFS found that low B2M (P 
.0001), MEL200 (P .0001), primary unresponsive disease (P
.004), and age 50 years or younger (P  .04) were statistically
signiﬁcant. B2M, MEL200, 12 months from diagnosis, and
age 50 years or younger were statistically signiﬁcant predictors
of prolonged OS.
Siegel et al. compared tandem transplantation in a sample of
49 patients with advanced stage MM aged 65 years or older to
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pair-mates younger than 65 years matched on 5 prognostic
factors (cytogenetics, B2M, C-reactive protein, albumin, and
creatinine) [71]. All patients received MEL (200 mg/m2) as the
conditioning regimen for the ﬁrst transplantation. If PR was
achieved/maintained after the ﬁrst, MEL200 was used again for
the second SCT; if PR was achieved/maintained, then
MEL140 plus TBI (850-1125 cGy) or MEL200 plus Cy (6
g/m2) was given as the preparative regimen. Median durations of
EFS and OS and TRM were not signiﬁcantly different between
the younger and older groups. Multivariate analysis identiﬁed un-
favorable cytogenetics and elevated B2M as signiﬁcant predictors
of poor EFS and OS; age younger than 65 years, however, was not
a statistically signiﬁcant factor for either EFS or OS.
Bjo¨rkstrand et al. reported on 15 patients with MM
intended to have tandem autotransplantations [72]. BM (n 
13) or PBSCs (n  2) were used for the ﬁrst transplantation
and PBSCs (n  11) were used for all second transplantations.
Conditioning regimen was MEL (200 mg/m2) for the ﬁrst
transplantation and MEL (140 mg/m2) plus TBI (1000 cGy)
for the second. Four patients did not receive the second
transplant due to incomplete hematopoietic reconstitution
(n  3) or TRM (n  1). Analysis of molecular remission was
performed using Ig gene ﬁngerprinting in 5 of 8 patients in
CR after the second transplantation. The original clonal band
was not detected in 4 of the 5 patients a median 27 months
after second transplantation. A new band was detected in 1
patient 32 months after the second transplantation, who 4
months later demonstrated clinical disease progression. At a
median 20.7 months after the ﬁrst transplantation, 8 patients
were in continuous CR, 3 in continuous PR, 2 were alive with
progressive disease, 1 died of treatment-related toxicity, and
1 died of progressive disease.
Autologous SCT Conditioning Regimens
Table 10 summarizes the evaluation of the quality and
strength of the evidence, patient characteristics, and outcomes
of the articles reviewed in this section.
Moreau et al. performed a randomized multicenter clinical
trial of 142 patients with MM treated with MEL (200 mg/m2)
versus 140 patients treated with MEL (140 mg/m2) plus TBI
(800 cGy) as the conditioning regimen for autologous PBSCT
[73]. Eligibility criteria included age younger than 65 years and
newly diagnosed, previously untreated, and symptomatic MM.
After enrollment, patients received VAD x 3 cycles, stem cell
mobilization with G-CSF, G-CSF plus stem cell factor (SCF) or
Cy (4 gm/m2) plus G-CSF, PBSC collections (if no disease
progression after VAD), 1 additional VAD cycle, and random-
ization to 1 of the conditioning regimens. PBSCT was then
performed and maintenance IFNa (3 x 106 U subcutaneously, 3
times per week) was given until disease progression, severe and
persistent side effects, or physician discretion to discontinue
IFNa occurred. Three hundred and ninety-nine patients were
enrolled in the trial; 101 were excluded during the VAD regi-
men due to disease progression (39%), severe infectious com-
plications (29%), or multiple other reasons (33%). Two hun-
dred and ninety-eight patients were randomized, 16 of whom
were inevaluable for PBSCT because of progression before
transplantation (n  7), patient decision to withdraw (n  4),
death from infection before PBSCT (n  2), protocol violation
(n 2), or suicide (n 1). Thus, 282 patients were evaluable for
outcomes after PBSCT.
Duration of neutropenia, thrombocytopenia, hospitaliza-
tion, and use of intravenous antibiotics were all signiﬁcantly
shorter in the MEL group (all comparisons, P  .001). Platelet
and red blood cell transfusion requirements also were signiﬁ-
cantly less in the MEL group (both P  .001). Grade 3-4
mucositis was less frequent in the MEL group (30% versus 51%;
P  .001). The CR rate was not different between the two arms
(35% MEL versus 29% MEL plus TBI; P  .41); the CR plus
very good PR rate was slightly higher in the MEL group (55%
versus 43%: P  .06). At a median follow-up of 20.5 months in
the MEL group and 20 months in MEL plus TBI group, the
45-month OS rate was 65.8% in the MEL group versus 45.5%
in the MEL plus TBI group (P  .05), the median OS was not
yet reached in the MEL group and was 43 months in the MEL
plus TBI group (Figure 6). Median EFS was not signiﬁcantly
different: 20.5 months in the MEL group versus 21 months in
the MEL plus TBI group, P  .6 (Figure 7).
Seven studies have described the feasibility and efﬁcacy of
novel conditioning regimens [74-83]. Five studies have ret-
Table 9. Comparison of Patient Characteristics and Outcomes from Articles Included in the Autologous Tandem versus Single SCT Section
Reference
Quality
of
Evidence*
Number
of Patients
in Study
Upper
Age Limit
(Median)
DS
Stage III TRM
Median F/U
(mos)
Strength of
Evidence—
OS*
Median
OS
(mos)
Strength of
Evidence—
EFS*
Median
EFS
(mos)
Barlogie et al. [69] 2-1 Enrolled 231
2 BMTs 165
71 (51) 53% 5% NS NC 68 NC 43
Vesole et al. [70] 2-2 MEL100 47
MEL140 21
MEL200 67
NS NS MEL100 19%
MEL140 24%
MEL200 1%
NS 1† MEL100 7
MEL140 16
MEL200 NYR
(43)
1‡ MEL100 5
MEL140 8
MEL200 21
Siegel et al. [71] 2-2 <65 49
>65 49
<65 64 (52)
>65 76 (67)
<65 49%
>65 59%
<65 2%
>65 8%
NS
(minimum
18 months)
3 <65 57.6
>65 39.6
3 <65 33.6
>65 18
Bjorkstrand et al.
[72]
2-1 1 BMT 15
2 BMTs 11
57 (48) 73% 7% 21 (after first
transplantation)
NC NYR (19) NC NS
DS indicates Durie-Salmon; TRM, treatment-related mortality; F/U, follow-up; OS, overall survival; EFS, event-free survival; NS, not stated in
article; NC, no comparison given in article.
*Quality of evidence deﬁnitions are listed in Table 1; strength of evidence deﬁnitions are listed in Table 2; †P  .001; NYR, not yet reached;
‡P  .0001.
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rospectively compared SCT conditioning regimens for single
transplantations [84-90], one study for tandem transplanta-
tion [91]. Bensinger et al. reported busulfan plus MEL plus
thiotepa had signiﬁcantly lower TRM than busulfan plus Cy
or busulfan plus Cy plus TBI [85] and Chen et al. reported a
signiﬁcantly higher TRM with etoposide plus MEL plus TBI
compared with busulfan plus Cy [88]. Three studies found no
signiﬁcant differences between conditioning regimens
[84,86,87,89,90], in which one performed 1-, 2-, 4-, and
6-month landmark multivariate analyses [84] and one found
no signiﬁcant independent prognosis for OS or EFS by con-
ditioning regimen in a multivariate analysis of registry data
[89,90]. Desikan et al. retrospectively compared conditioning
regimens for the second SCT of a planned tandem transplan-
tation and determined EFS (P  .0001) and OS (P  .003)
rates were signiﬁcantly better in patients who received MEL
(200 mg/m2) versus MEL (200 mg/m2) plus Cy or MEL (140
mg/m2) plus TBI [91].
Autologous High-Dose Sequential Therapy
Palumbo et al. investigated an intensiﬁed regimen in 68
patients newly diagnosed with MM treated with dexamethasone,
Adriamycin, and vincristine (DAV) x 3 cycles for induction
therapy [92,93]. Their median age was 65 years (upper limit, 73
years); 64% had stage III disease. Cy (3 g/m2) was administered
on day 0 plus G-CSF on days 3 to 9, followed by PBSC
collection on day 10, MEL (60 mg/m2) on day 11, and PBSC
re-infusion on day 12 (CM regimen). The CM regimen was
given a total of 3 times at 6-month intervals. By intent-to-treat,
50% (34/68) of patients completed the program. Reasons for
failure to complete 3 CM regimens were as follows: relapse (n
14), low CD34 cell yield (n  8), toxicity during CM regimen
(n  7), toxicity after DAV (n  4), and secondary neoplasm
(n  1). By intent-to-treat, CR was induced in 27% of patients;
CR plus PR was induced in 85%. TRM was 3%; median EFS
was 35.6 months.
Table 10. Comparison of Patient Characteristics and Outcomes from Articles Included in Autologous SCT Conditioning Regimen Section
Reference
Quality
of
Evidence*
Conditioning Regimen
(number of patients; dose)
Upper
Age Limit
(Median; number in
category)
DS
Stage
III TRM
Median
F/U
(mos)
Strength of
Evidence—
OS*
Median
OS
(mos)
Strength of
Evidence—
EFS*
Median
EFS
(mos)
Moreau et al. [73] 1 Mel 200 (142) vs.
Mel 140 TBI 800 (140)
65 (61)
65 (60)
75%
79%
0%
4%
20.5
20
1† NYR
43
3 20.5
21
Tribalto et al. [74] 2-1 Bu 16 Mel 60 (39) 60 (49) 48% 3% 55 NC 57 NC 21
Meloni et al. [76] 2-1 Ida Bu Mel 60 (28) 69 (55) 57% 0% 20 NC NS NC NS
Mansi et al. [77] 2-1 Bu 8 or 16 (15) 64 (52) NS 20% 7 NC 8 NC NS
Long et al. [78] 2-1 VCTBI (12) or
CBV (22)
65 (49) 47% 6% 38 NC NS NC NS
Shimoni et al. [80] 2-1 TtBuC (120) 67 (48) 57% 13% 29 NC NS NC NS
Alegre et al. [82] 2-1 Bu 12Mel 140 (24) 60 (48) 79% 4% 20 NC NS NC NS
Ventura et al. [83] 2-1 CBV (11) NS NS 9% NS NC 12 NC NS
Barlogie et al. [84] 2-2 Mel 100 (46) vs.
Mel 100GM (24) vs.
Mel 140ABMT (8) vs.
Mel 140TBIABMT (37) vs.
TtTBIABMT (18)
NS NS 28%
17%
13%
11%
0%
108 1‡ 4.8
21.6
8.4
33.6
22.8
1§ 2.4
6
4.8
15.6
7.2
Bensinger et al. [85] 2-1 Bu 14-16 C 120-174 (18) vs.
Bu 14 C 120 TBI 600-1050
(36) vs.
Bu 12 Mel 100 Tt500 (9)
66 (51) 43% 28%
14%
11%
31.2 NC NS NC NS
Goldschmidt et al. [86] 2-1 Mel 200 (50) vs.
Mel140TBI (50)
65 (54)
60 (50)
80%
72%
0%
4%
16 NC NS NC NS
Chen et al. [88] 2-2 VMelTBI (94)
BuCy (32)
NS NS 14%
3%
11.8 NC NYR (58) NC NS
Lahuerta et al. [89] 2-2 Mel 200 (472)
Mel 140TBI (135)
BuMel (186)
BuC (28)
55
49
50
53
68%
68%
66%
66%
4%
8%
6%
0%
NS 3 46
39
57
39
3 22
20
30
23
Desikan et al. [91] 2-2 Second SCT:
Mel 200 (43)
Mel 200Cy 120 (19)
Mel 140TBI 1125 (24)
NS NS 0%
0%
8%
NS 1¶ 76
39
25
1# 61
27
15
Bu indicates Busulfan; Mel, melphalan; Ida, Idarubicin; V, Etoposide; C, Cyclophosphamide; TBI, total body irradiation; B, carmustine; Tt,
thiotepa; GM, GM-CSF; ABMT, autologous bone marrow transplantation; Second SCT, conditioning regimen for ﬁrst transplantation was Mel 200
whereas the second transplantation regimen varied as indicated; DS, Durie-Salmon; F/U, follow-up; OS, overall survival; EFS, event-free survival;
NC, no comparison given in article; NS, not stated in original article; NYR, not yet reached.
*Quality of Evidence deﬁnitions are listed in Table 1; Strength of Evidence deﬁnitions are listed in Table 2; †P  .05 comparing the rate of
45-month OS: 65.8% (MEL) vs. 45.5% (MEL plus TBI); ‡P  .0004; §P  .0001; means not medians, upper limit not stated; ¶P  .003 comparing
Mel200 vs. other; #P  .0001 comparing Mel200 vs. other.
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Prognostic Factors for OS, EFS, CR Rate, and
Favorable Engraftment in Patients Treated with
Autologous SCT
Table 11 summarizes the prognostic factors described in
this section. The following independent risk factors for
longer OS after SCT for MM have been described: non–
plasmablastic morphology [94], attainment of CR posttrans-
plantation [95], low B2M [96,97], IgG isotype of MM [96,98],
high glomerular ﬁltration rate [99], disease status at time of
SCT (in CR or having chemotherapy-responsive disease)
[96,97,100-103], MEL-containing conditioning regimen
[101], male gender [101], stage I disease at diagnosis [101],
C-reactive protein [103], early absolute lymphocyte count
recovery [104], plasma cell labeling index [104], circulating
plasma cells [104], no deletion of chromosome 13q14 [105],
and normal cytogenetics [106].
The following factors have been investigated for correlation
with OS or EFS and found not to be signiﬁcantly associated:
number of re-infused plasma cells (EFS) [107]; light chain as-
sociated amyloidosis (OS/EFS) [108]; and magnetic resonance
imaging 1 month before and after SCT (OS) [109].
In multivariate analyses of tandem PBSCT, a higher rate of
continuous CR was associated with low B2M, low C-reactive
protein (CRP), no chromosome 13 abnormalities, and less than
1 year of prior chemotherapy [110]. Longer EFS and OS was
associated with the absence of any chromosomal abnormalities
[111,112], absence of chromosome 11 and 13 abnormalities
[113], low B2M [111-113], low CRP [112], attainment of CR
[112], 2 PBSCTs given within a 6-month period [112], and
shorter duration of chemotherapy before ﬁrst SCT [111,113].
The following independent risk factors for rapid/favorable
engraftment after SCT for MM have been described: Cy plus
G-CSF (versus G-CSF alone) as the PBSC mobilization regi-
men and no prior oral MEL exposure predicted rapid platelet
engraftment [114]; no prior high-dose MEL exposure and 2 x
106 CD34 cells/kg infused predicted favorable neutrophil and
Figure 6. Survival according to treatment arm. Reprinted with permission [73].
Figure 7. Event-free survival according to treatment arm. Reprinted with permission [73].
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platelet recovery [115]; and the number of CD34 cells/kg
infused and duration of exposure to chemotherapy signiﬁcantly
correlated with neutrophil and platelet engraftment [116]. Pa-
tients with 24 months of chemotherapy required 2.0 x 106
CD34 cells/kg; however, patients with 24 months of prior
chemotherapy required 5.0 x 106 CD34 cells/kg to achieve
rapid neutrophil and platelet engraftment [116].
Other observations include the following: plasma cell
labeling index was signiﬁcantly higher in patients with abnor-
mal cytogenetics [107,117]; prolonged prior therapy with
alkylating agents (more than 1 prior cycle of chemotherapy
before SC mobilization) was associated with developing my-
elodysplastic syndrome (MDS) posttransplantation [118]; el-
evated plasma cell light chain ratio (LCR) in the ﬁrst 60 days
post-SCT most likely indicated residual tumor and not early
relapse, however, an elevated LCR 90 days post-SCT sig-
niﬁcantly correlated with disease progression [119]; failure to
achieve CR (as measured by electrophoresis and immunoﬁx-
ation) after SCT was independently predicted by prior ther-
apy with 2 or more chemotherapy regimens, non-responsive
disease at time of SCT, and TBI-containing conditioning
regimen [120].
Table 11. Summary of Prognostic Factors for OS, EFS, CR Rate, and Favorable Engraftment in Patients Treated with Autologous SCT
Reference No. Factors
Independent laboratory indicators of prolonged OS
94 Non-plasmablastic morphology
3,70,96,97 Low B2M
103 Low C-reactive protein
96,98 IgG isotype
99 High glomerular filtration rate
104 Early absolute lymphocyte count recovery
105 No deletion of chromosome 13q14
106 Normal cytogenetics
Independent clinical indicators of prolonged OS
16,96,97,100-103 Disease status at time of SCT (in CR or with chemotherapy-responsive disease)
14,15,16 SCT as de novo therapy (vs. salvage)
7,95 Achievement of CR post-SCT
21,24 Autologous SCT (vs. allogeneic)
101 Melphalan-containing conditioning regimen
101 Male gender
101 Stage I disease at diagnosis
11 Younger age
Clinical and laboratory indicators that are not significant predictors of OS or EFS
107 Number of reinfused plasma cells (EFS)
108 Light chain associated amyloidosis (OS/EFS)
109 Magnetic resonance imaging pattern 1 mo before and after SCT (OS)
Clinical and laboratory indicators in tandem PBSCT
Higher CR rate
110 Low B2M
110 Low C-reactive protein
110 No chromosome 13 abnormalities
110 Less than 1 y of prior chemotherapy
Prolonged OS and EFS
69,71,111-113 Absence of chromosomal abnormalities
69-71,111-113 Low B2M
112 Low C-reactive protein
112 Attainment of CR
112 Two PBSCTs given within a 6-month period
111,113 Shorter duration of chemotherapy before first PBSCT
Clinical and laboratory indicators for favorable/rapid engraftment after SCT
Platelet engraftment
114 CyG-CSF (vs. G-CSF alone) as SC mobilization regimen
114 No prior oral MEL exposure
Neutrophil and platelet engraftment
115 No prior MEL exposure
115 >2  106 CD34 cells/kg infused
116 Duration of prior chemotherapy
116 Number of CD34 cells infused
116 <24 months of prior chemotherapy needs >2.0  106 CD34 cells/kg
116 >24 months of prior chemotherapy needs >5.0  106 CD34 cells/kg
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SYNGENEIC SCT
Gahrton et al. performed a retrospective case-matched anal-
ysis of 25 patients with MM treated with BMT (n  24) or
PBSCT (n  1) from syngeneic donors to 125 autologous SCT
patients and 125 allogeneic SCT patients reported to the EBMT
Registry [121]. Matching criteria was based on previously iden-
tiﬁed prognostic factors. For autologous SCT, factors used for
matching were number of prior therapies (0-1 versus 2), dis-
ease status at time of SCT (CR versus PR versus no response/
progressive disease), and the nearest possible date of SCT. For
allogeneic SCT, factors used for matching were number of prior
therapies (0-1 versus 2), gender of the recipient, and nearest
possible date of SCT. Five autologous SCT and ﬁve allogeneic
SCT patients were matched to each syngeneic SCT. Compared
with autologous SCT patients, syngeneic SCT patients had an
improved median OS (73 versus 44 months; P  .10), signiﬁ-
cantly better median PFS (72 versus 25 months; P .0088), and
signiﬁcantly lower risk of relapse (36% versus 78% at 48
months; P  .0094). Compared with allogeneic SCT patients,
syngeneic SCT patients had a signiﬁcantly better median OS (73
versus 16 months; P  .0083), signiﬁcantly better median PFS
(72 versus 9 months; P value was “signiﬁcantly different” but was
not stated quantitatively), but had no difference in the relapse
rate (36% versus 40% at 48 months; P .99). The overall TRM
rate was 40% in the allogeneic SCT group and 8% in the
syngeneic SCT group, but was not stated in the autologous SCT
group.
Bensinger et al. described 11 patients with MM given sal-
vage therapy with a BMT (n  10) or PBSCT (n  1) from
syngeneic donors [122]. Median age was 48 years (range, 36 to
61 years), 10 patients had stage III disease and 2 patients had
chemotherapy-sensitive disease at the time of SCT. Median
time from diagnosis to SCT was 353 days (range, 176 to 6118
days). Conditioning regimens included Cy plus TBI (1200 cGy
in 6 fractions; n 8), busulfan plus Cy (n 1), busulfan plus Cy
plus TBI (750 cGy in 5 fractions; n  1), or busulfan plus MEL
(100 mg/m2) plus thiotepa (n  1). Two patients (18%) died
within 100 days post-SCT of transplant-related causes. Five
patients (45.5%) achieved a CR post-SCT; however, 3 of these
patients relapsed on days 539, 737, and 1706, respectively,
and subsequently died. One patient died of secondary MDS; 2
patients are long-term survivors (9 and 15 years).
ALLOGENEIC SCT
Table 12 summarizes the evaluation of the quality and
strength of the evidence, patient characteristics, and outcomes
of the articles reviewed in this section.
Gahrton et al. retrospectively reviewed 90 patients who
received allogeneic BMTs from HLA-identical sibling donors
and were reported to the EBMT Registry between 1983 and
1989 [123-126]. Median time from diagnosis to BMT was 19
months (range, 3 to 85 months). For induction therapy, 32
patients received intermittent MP and 58 patients received 1 of
32 different drug combinations, most containing either MEL or
Cy plus other drugs. At the time of allogeneic BMT, 7 (8%)
patients were in CR, 34 (38%) in PR, and 49 (54%) were
non-responders or had progressive disease. Conditioning regi-
mens were Cy plus TBI (n  33), Cy plus TBI plus other drug
combinations (n 43), MEL plus TBI (n 5), Cy plus busulfan
(n  6), MEL plus Cy (n  2), and Cy plus other drugs (n  1).
GVHD prophylaxis consisted of methotrexate plus cyclosporine
(n  34), cyclosporine alone (n  10), methotrexate plus cyclo-
sporine plus prednisolone (n  7), cyclosporine plus pred-
nisolone (n  3), methotrexate alone (n  3), or methotrexate
plus prednisolone (n  2). Thirty-one patients received T-
cell depleted BM grafts with or without additional GVHD
prophylaxis regimens.
Eighteen patients (20%) died before engraftment. By in-
tent-to-treat, 39 (43%) achieved a CR post-BMT and 8 (9%)
developed grade III or IV acute GVHD. Median OS was 26
months. No pretreatment factors signiﬁcantly predicted OS,
although there were trends toward improved OS in patients who
had stage I disease, were in CR at time of BMT, had received
only 1 prior chemotherapy regimen, and underwent BMT
within 12 months of diagnosis. Remission status post-BMT (ie,
patients who achieved CR) signiﬁcantly predicted longer OS (P
 .0001) as did grade I acute GVHD (P  .004). At an average
of 79 months after the start of the study, 43 patients have died
of various causes including interstitial pneumonia (n  9), MM
(n 8), acute GVHD (n 6), bacterial or fungal infections (n
6), hemorrhage (n  5), organ failure (n  4), graft failure (n 
2), adult respiratory distress syndrome (n  2), or secondary
leukemia (n  1).
LeBlanc et al. reported on 37 patients with MM treated with
an allogeneic BMT (n  18) or PBSCT (n  19) from HLA-
Table 12. Comparison of Patient Characteristics and Outcomes from Articles Included in the Allogeneic SCT Section
Reference No.
Quality of
Evidence*
Number
of Patients
in Study
Upper
Age Limit
(Median)
DS
Stage
III TRM
Median
F/U (mos)
Strength of
Evidence—
OS*
Median
OS
(mos)
Strength of
Evidence—
EFS*
Median
EFS
(mos)
Gahrton et al. [123] 2-2 90 55 (42) 68% NS 79 (mean) NC 26 NC NS
LeBlanc et al. [127] 2-1 37 53 (47) 68% 16%† 40 NC NS NC NS
Reece et al. [128] 2-1 26 54 (43) 81% 19%‡ 14 NC NS NC NS
Majolino et al. [129] 2-1 10 53 (45) 80% 20%† 16.5 NC NYR (14) NC NS
DS indicates Durie-Salmon; TRM, treatment-related mortality; F/U, follow-up; OS, overall survival; EFS, event-free survival; NC, no comparison
given in article; NYR, not yet reached.
*Quality of Evidence deﬁnitions are listed in Table 1; Strength of Evidence deﬁnitions are listed in Table 2; †TRM by day 120 post-SCT; ‡TRM
by day 100 post-SCT.
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identical (6/6 match) (n 37) or single antigen mismatched (5/6
match) (n  1) sibling donors between 1990 and 2000 [127].
The median number of prior chemotherapy regimens was 1
(range, 1 to 4) including 6 patients who had undergone a prior
autologous SCT. Median time from diagnosis to SCT was 9.3
months (range, 4 to 41 months), with 17 (46%) patients in CR
and 9 (24%) in PR at the time of SCT, whereas 6 (16%) had
stable disease and 5 (14%) were unevaluable. Conditioning reg-
imens consisted of Cy plus TBI (n  25), busulfan plus Cy (n 
7), MEL plus TBI (n  3), busulfan plus Cy plus MEL (n  1),
or BCNU plus etoposide plus cytosine arabinoside plus CY (n
1). GVHD prophylaxis comprised cyclosporine and methotrex-
ate. Nine patients (24%) developed grade III or IV acute
GVHD; 14 (38%) developed extensive chronic GVHD.
Twenty-ﬁve patients (68%) were evaluable for response, but, by
intent-to-treat analysis, 41% (15/37) achieved a CR post-allo-
geneic SCT, 19% (7/37) achieved a PR, and 8% (3/37) died of
progressive disease. The Kaplan-Meier estimate of OS at 40
months was 32%.
Reece et al. studied 26 patients with MM treated with
allogeneic BMT from an HLA-matched sibling (n  19), HLA-
mismatched relative (n  3), or unrelated (n  4) donor [128].
Median time from diagnosis to BMT was 4 months (range, 2-58
months) with a median 1 prior chemotherapy regimen (range,
1-5). At the time of allogeneic BMT, 21 patients (81%) had
chemotherapy-sensitive disease. Conditioning regimens con-
sisted of busulfan plus Cy plus MEL (n  14), busulfan plus Cy
(n  8), or Cy plus TBI (n  4), and GVHD prophylaxis
consisted of cyclosporine plus methotrexate with or without
XomaZyme (n  21) or cyclosporine plus methylprednisolone
(n 5). Acute GVHD grade II to IV occurred in 20 patients and
was fatal in 3 patients. Of the 26 allogeneic BMT patients, 13
(50%) achieved a CR, 6 (23%) a PR, 2 (8%) had no response,
and 5 (19%) were not evaluable for disease response posttrans-
plantation. At a median follow-up of 14 months, the 3-year OS
and PFS rates were 46.5% (95% CI, 20%-69%) and 40% (95%
CI, 19%-61%), respectively. The PFS rate of the patients with
chemotherapy-resistant disease at time of BMT was signiﬁcantly
lower than patients with chemotherapy-sensitive disease at time
of BMT (0% versus 52%; P  .0066).
Majolino et al. studied 10 patients with MMwho underwent
allogeneic PBSCT from HLA-identical sibling donors [129]. At
time of PBSCT, 3 patients were in CR, 3 in PR, 3 had relapsed
disease, and 1 had progressive disease. Donor PBSCs were
mobilized with G-CSF (n 6) or GM-CSF followed by G-CSF
(n  4). Conditioning regimens included busulfan plus MEL
(n  9) or busulfan plus Cy (n  1). All patients received
cyclosporine plus methotrexate as GVHD prophylaxis. Acute
GVHD grade II developed in 3 patients and grade III developed
in 1 patient. Eight patients achieved a CR and 2 achieved a PR
post-PBSCT. At a median 18.5 months post-PBSCT, 8 patients
were alive, including 6 in CR.
Allogeneic PBSCT versus BMT
Gahrton et al. retrospectively compared 690 patients who
underwent allogeneic transplantation reported to the EBMT
Registry between 1983 and 1998, including 334 BMTs be-
tween 1983 and 1993 (historic BMT group), 223 allogeneic
BMTs between 1994 and 1998 (concurrent BMT group), and
133 PBSCTs between 1994 and 1998 (PBSCT group) [130].
Time to neutrophil and platelet engraftment did not differ
between the historic and concurrent BMT groups, whereas
engraftment times in the PBSCT group were signiﬁcantly
shorter when compared with either the historic or concurrent
BMT groups. The incidence of acute and chronic GVHD was
not signiﬁcantly different between the 3 groups: grade III/IV
acute GVHD 16% historic BMT versus 11% concurrent
BMT versus 18% PBSCT groups; chronic GVHD 27% ver-
sus 11% versus 17%, respectively. The authors postulate the
rate of chronic GVHD was higher in the historic BMT group
due to a longer follow-up period, although the speciﬁc me-
dian follow-up times for the 3 groups were not stated in the
report. Median OS was signiﬁcantly prolonged in the con-
current BMT group compared with the historic BMT group
(50 months versus 10 months; P  .0001), but there was no
signiﬁcant difference between the PBSCT (median OS not
yet reached) and concurrent BMT groups. TRM at 6 months
was signiﬁcantly reduced in the concurrent versus historic
BMT groups (6-month TRM rate, 38% versus 21%) but was
not signiﬁcantly different between the PBSCT and concur-
rent BMT groups (the TRM rate for the PBSCT group was
not stated in the original article). Median PFS was signiﬁ-
cantly longer in the concurrent BMT group compared with
the historic BMT group (19 months versus 7 months; P 
.0001) but did not signiﬁcantly differ between the concurrent
BMT and PBSCT (15 months) groups.
Allogeneic SCT Conditioning Regimens
Cavo et al. investigated the feasibility and efﬁcacy of busul-
fan (16 mg/kg) plus Cy (200 mg/m2) as an alternative condi-
tioning regimen for allogeneic BMT with HLA-compatible sib-
ling donors in 19 patients with MM [131]. Twelve (63%)
patients failed to respond to prior chemotherapy, whereas 7
(37%) had chemotherapy-sensitive disease. GVHD prophylaxis
was cyclosporine plus methotrexate (n  16) or T-cell depletion
plus Campath with or without cyclosporine (n  3). Neutrophil
recovery was achieved by 18 (95%) patients at a median of 18
days (range, 12 to 22 days) post-allogeneic BMT; graft failure
occurred in 1 T-cell depleted allogeneic BMT patient who died
of cerebral hemorrhage on day 36. Six patients (33%) devel-
oped grade II to IV acute GVHD; 1 patient each had limited or
extensive chronic GVHD. Six patients died of treatment-related
complications before day 100. At a median follow-up of 66
months, 14 patients have died of progressive MM (n  7) or
treatment-related causes (n 7). Median OS was 21 months and
median EFS was 12 months. Chemotherapy sensitivity was a
signiﬁcant predictor of prolonged OS (4-year OS rate, 71%
versus 0%; P  .0004) and EFS (4-year EFS rate, 57% versus
0%; P  .01).
Badros et al. reported on 31 patients with MM given allo-
geneic PBSCT with a non-myeloablative conditioning regimen
and an HLA-compatible sibling (n  25) or unrelated (n  6)
donor [132]. All but 1 patient had received 1 (n 13) or2 (n
17) prior autologous transplantation. The non-myeloablative
conditioning regimen was MEL (100 mg/m2) for related allo-
grafts and MEL (100 mg/m2) plus TBI (250 cGy) plus ﬂudara-
bine (30 mg/m2) for unrelated allografts. Patients with related
donors received unmanipulated PBSCs collected after G-CSF
mobilization. Among patients with unrelated donors, 3 received
PBSCs collected after G-CSF mobilization (2 of whom were
CD34 selected/T-cell depleted) and 3 received unmanipu-
lated, unmobilized BM. GVHD prophylaxis consisted of cy-
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closporine for related allografts and cyclosporine plus meth-
ylprednisolone for unrelated allografts. Patients with no
evidence of GVHD were initially scheduled to receive donor
lymphocyte infusions (DLIs) on days 21, 42, and 112 to
achieve full chimeric engraftment. The duration of cyclo-
sporine was doubled, however, due to a high incidence of
GVHD, after which 18 patients were given DLIs based on
disease and chimerism status.
One patient with a related donor and 2 patients with unre-
lated donors died of TRM before day 100 post-allogeneic
SCT. Two patients failed to demonstrate myeloid engraftment
even after a second allogeneic PBSC infusion; both received an
autologous PBSC rescue with 1 alive in near CR and 1 dead of
progressive disease. The remaining patients achieved neutrophil
recovery at a median of 14 days (range, 10 to 46 days) and
platelet recovery at a median of 15 days (range, 0 to 50 days)
post-allogeneic PBSCT. Eighteen patients developed grade II to
IV acute GVHD, 12 of whom developed acute GVHD after
DLI. Ten patients developed chronic GVHD, 6 with extensive
involvement. Twenty-two patients (71%) had at least a PR to
the allograft. At a median follow-up of 6 months (range, 1.5 to
24 months), 19 patients are alive in CR or near CR. The median
OS was 15 months.
Patients given nonmyeloablative conditioning (n 31) were
compared with historical controls treated with myeloablative
regimens (n  93, mostly TBI-based regimens). TRM in the
ﬁrst 100 days post-allogeneic SCT was signiﬁcantly lower in the
nonmyeloablative regimen group (10% versus 29%; P  .03). A
multivariate analysis determined nonmyeloablative conditioning
regimen to be the only clinical risk factor predictive of pro-
longed OS (P  .007).
Prognostic Factors for PFS, OS, and EFS in Patients
Treated with Allogeneic SCT
Table 13 summarizes the prognostic factors described in
this section. Gahrton et al. analyzed the prognostic factors for
allogeneic BMT using matched sibling donors in 162 patients
with MM reported to the EBMT Registry between 1983 and
1993 [133]. Patients were heterogeneous with respect to pre-
transplantation disease characteristics, duration and regimens of
prior chemotherapy, conditioning regimens, GVHD prophy-
laxis, and supportive care. By univariate analysis, favorable pre-
dictors of OS were female gender (P  .04), stage I disease at
diagnosis (P  .05), 1 prior chemotherapy regimen (P  .02), in
CR at time of BMT (P  .05), achievement of CR post-BMT
(P  .001), and no grade III or IV acute GVHD (P  .02).
Trends toward signiﬁcance were found for IgA subtype MM
(P  .08) and low B2M (4 g/L; P value not stated). Multivar-
iate analysis failed to identify any statistically signiﬁcant inde-
pendent pre-BMT predictors of OS (the strongest tendency was
for female gender; P  .07). Multivariate analysis identiﬁed
acute GVHD grade III or IV (P  .0006) as the most signiﬁcant
post-BMT factor with an adverse effect on OS, whereas a
signiﬁcant positive effect on OS was identiﬁed in patients who
achieved a CR post-BMT (P  .01).
Bensinger et al. determined the prognostic factors for 80
patients with MM treated with allogeneic BMT from related
(n  71) or unrelated (n  9) donors between 1987 and 1994
[134]. Conditioning regimens were busulfan plus Cy (n  57)
or busulfan plus Cy plus TBI (n  23). GVHD prophylaxis
consisted of cyclosporine plus methotrexate (n  46), cyclo-
sporine plus methylprednisolone (n  22), FK506 (Tacroli-
mus) (n  8), cyclosporine alone (n  3), or T-cell depletion
(n  1). TRM within 100 days post-BMT was 44% (35/80).
Statistically signiﬁcant risk factors for adverse outcome by
multivariate analysis were elevated B2M (2.5 g/L: P  .009)
and time from diagnosis to transplantation greater than 1 year
(P  .033). Factors that were considered in the multivariate
model but that were not signiﬁcant independent predictors
were age, sex, number of chemotherapy cycles and regimens,
plasma cells 10%, prior radiation therapy, stage III disease,
chemotherapy sensitivity, TBI-containing conditioning regi-
men, and donor type.
Kulkarni et al. identiﬁed signiﬁcant prognostic factors in a
study of 33 patients with MM treated with allogeneic BMT (n
29) or PBSCT (n  4) from related (n  29) or unrelated (n 
4) donors between 1981 and 1998 [135]. Conditioning regimens
included the following: MEL (110 mg/m2) plus TBI (single
fraction 950-1050 cGy) (n  22), busulfan plus Cy (n  3), Cy
plus TBI (single fraction 950-1050 cGy) (n  3), Cy plus MEL
plus Campath plus TBI (1200 cGy in 6 fractions) (n  3),
busulfan plus MEL (n  2), or MEL plus TBI (1200 cGy in 6
fractions) (n  1). GVHD prophylaxis consisted of cyclosporine
plus methotrexate (n  29) or cyclosporine alone (n  4). TRM
within 150 days post-SCT was 51.5%. Grade III or IV acute
GVHD developed in 30% of patients. At a median follow-up of
27 months, the 2-year EFS rate was signiﬁcantly less in patients
who had a prior autologous SCT compared with those who did
not (16.7% versus 47.9%; P  .019). Patients with a creatinine
clearance of 100 mL/min at time of SCT had a signiﬁcantly
improved EFS rate compared with those with 100 mL/min
(72.7% versus 21.8%; P  .013).
Badros et al. retrospectively analyzed the effect of ABO
mismatches in 27 patients with MM who received nonmyelo-
ablative conditioning regimens [136]. Three patients had minor
and 6 had major ABO mismatched allogeneic grafts. The 3
patients with minor ABO mismatches showed evidence of he-
molysis, but all 3 converted to the donor ABO group. Three of
the major ABO mismatched patients developed grade II to III
Table 13. Summary of Prognostic Factors for PFS, OS, and EFS in
Patients Treated with Allogeneic SCT
Reference No. Factors
Statistically significant independent indicators of prolonged PFS
126 Chemotherapy-sensitive disease at time of SCT
134 <Stage III disease
Statistically significant independent indicators of prolonged OS
123,133 Achievement of CR post-SCT
123 Grade I acute GVHD
133 <Grade III acute GVHD
134 Chemotherapy-sensitive disease at time of SCT
134 Low B2M (<2.5 g/L)
134 Less than 1 y between diagnosis and SCT
127 Fewer cycles of chemotherapy prior to allogeneic SCT
Statistically significant independent indicators of prolonged EFS
131 Chemotherapy-sensitive disease at time of SCT
135 No prior autologous SCT
135 Creatinine clearance > 100 mL/min
T. Hahn et al.
22
acute GVHD before converting to the donor ABO group, 1
failed to engraft and had autologous reconstitution, 1 developed
red blood cell aplasia, and 1 remained a mixed chimera even
after 3 DLIs. No ABO-matched patients had graft failure. ABO
mismatch did not correlate with OS or incidence of acute
GVHD.
THERAPY POST-SCT
IFNa Maintenance Therapy Post-SCT
Attal et al. demonstrated the feasibility and safety of using
maintenance IFNa therapy after autologous BMT in a study
of 20 patients with MM in ﬁrst PR [137]. Conditioning
regimen was MEL (140 mg/m2) plus TBI (800 cGy in 4
fractions with no lung shielding). IFNa (3 x 106/m2 subcuta-
neously 3 times per week) was started when good perfor-
mance status (World Health Organization 2), granulocytes
500 x 106/L, and platelet count 75 x 109/L were achieved
(median, 2.7 months post-BMT) and was continued until
relapse. No patients died of toxicity from the transplant or
IFNa. At a median follow-up post-BMT of 13 months, 18
patients remained progression-free and 2 have relapsed re-
sulting in a 2-year PFS rate of 85%. At last follow-up, all
progression-free patients were still receiving IFNa without
dose reduction. One patient required a transient interruption
in IFNa therapy due to thrombocytopenia.
Cunningham et al. performed a randomized trial to evaluate
the role of IFNa maintenance therapy post-BMT [138]. At the
time of hematologic recovery (white blood cell (WBC) count
2 x 109/L and platelets 100 x 109/L, median 62 days post-
BMT), 84 patients were randomly assigned to maintenance
IFNa administered subcutaneously 3 times per week at a dose of
3 x 106 units/m2 until relapse (n  42, IFNa arm) or to no
further therapy post-BMT (n  42, control arm). Patients re-
ceived MEL (100-200 mg/m2) plus BMT (n  35 IFNa, 34
control arm), MEL (140 mg/m2) without stem cell rescue (n 
5 IFNa, 7 control arm), or busulfan (16 mg/kg) plus BMT (n 
2 IFNa, 1 control arm) as conditioning regimen.
At a median follow-up of 52 months, the median PFS after
BMT was 46 months in the IFNa arm versus 27 months in the
control arm (P .025) and OS after BMT was 88% versus 67%,
respectively (P  .006). At a median follow-up of 77 months,
however, the PFS and OS were not signiﬁcantly different: 31
patients in the IFNa arm and 33 patients in the control arm
relapsed (P  .11) (Figure 8) and 17 patients in the IFNa arm
and 21 patients in the control arm died (P  .106).
Powles et al. studied a consecutive series of 195 patients
with newly diagnosed untreated MM aged younger than 70
years from September 1986 to March 1994 [139]. All patients
were intended to complete a sequential therapy regimen con-
sisting of induction, high-dose therapy with stem cell support,
and maintenance IFNa. A total of 57 patients received IFNa as
maintenance, 46 of whom also were enrolled in the randomized
trial by Cunningham et al. Median OS and PFS were longer for
patients who underwent transplantation who received mainte-
nance IFNa (n  57) than those who did not (OS: not yet
reached at 8 years versus not stated in article; PFS: 44 versus 21
months; P  .0036).
Powles et al. also compared the IFNa tolerance of patients
who had received autologous BMT (n  37) with those who
received PBSCT (n  39), and also compared engraftment,
response, and survival in autologous BMT (n  21) with PB-
SCT (n  15) patients [140]. Again, these patients overlapped
with those in the Cunningham et al. randomized trial and the
Powles et al. study discussed above. INFa was initiated at a
median of 58 days post-BMT and 61 days post-PBSCT and
given 3 times per week at a dosage of 3 x 106/m2 after hemato-
poietic recovery (WBC count 2 x 109/L and platelets 50 x
Figure 8. Probability of progression-free survival of all patients by the Kaplan-Meier method. Reprinted with permission [138].
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109/L). There was no signiﬁcant difference between the 2
groups with regard to toxicity. BMT and PBSCT patients had
comparable IFNa dose modiﬁcation, discontinuation of treat-
ment, and break in treatment. PBSCT patients had faster neu-
trophil engraftment (17 versus 22 days; P value not signiﬁcant)
and signiﬁcantly faster platelet engraftment (15 versus 26 days;
P  .005) than BMT patients. There was no signiﬁcant differ-
ence between the PBSCT and BMT groups with respect to CR
rate (60% versus 80%), 2-year OS rate (79% versus 95%), or
2-year PFS rate (79% versus 81%).
Bjo¨rkstrand et al. performed a retrospective study of
IFNa maintenance therapy after SCT in patients reported to
the EBMT Registry between 1988 and 1998 [141]. Patients
who received IFNa maintenance, engrafted after a single
transplantation, and were in CR or PR 6 months after trans-
plantation (n  473) were case matched to patients who met
the same criteria but who did not receive IFNa maintenance
therapy (n  419). Several prognostic factors were signiﬁ-
cantly different between the IFNa and no IFNa groups;
however, they were statistically corrected for in the multivar-
iate analysis of survival.
Median OS was signiﬁcantly longer in the IFNa group
compared with the no IFNa group (78 versus 47 months; P 
.007). Patients who were in PR at 6 months posttransplantation
retained a signiﬁcantly longer median OS (97 versus 46 months;
P  .03), but no difference in median OS was demonstrated for
patients in CR at 6 months posttransplantation (64 versus 51
months; P .1). Median PFS also was signiﬁcantly longer in the
IFNa group compared with the no IFNa group (29 versus 20
months; P  .006). Patients in PR at 6 months posttransplan-
tation also retained a signiﬁcantly longer median PFS (31 versus
18 months; P  .003), however, patients in CR at 6 months
posttransplantation had no difference in median PFS (29 versus
22 months; P  .6).
DLI after SCT
Lokhorst et al. studied 27 patients with MM who received
52 DLI infusions at a median of 30 months post-allogeneic SCT
from a sibling donor [142,143]. Disease status at time of allo-
geneic SCT was refractory (n  11) or PR (n  16); no patients
were in CR at time of allogeneic SCT. In addition, all patients
who received DLI were refractory to or relapsed after their
allogeneic SCT. GVHD prophylaxis post-SCT consisted of a
partially T-cell depleted graft plus cyclosporine (n  25) or
cyclosporine plus methotrexate (n  2). Patients with active
GVHD were ineligible for DLI. DLI T-cell doses ranged from
1 x 106 to 5 x 108 cells/kg. Patients who had no response by 12
weeks post-DLI were eligible to receive additional DLI courses
with escalated T-cell doses.
Eight patients (30%) achieved PR, and 6 (22%) achieved
CR after 1 (n  8), 2 (n  1), 3 (n  2), or 4 (n  3) DLIs. Five
patients were still in remission 30 months post-DLI. Fifteen
patients (56%) developed acute GVHD post-DLI, including 4
with grade III GVHD. Seven patients (26%) developed chronic
GVHD post-DLI, including 3 patients with extensive chronic
GVHD. Median OS of the 27 patients was 18 months with 13
survivors. By multivariate analysis, the only factors predictive of
response to DLI were T-cell dose 1.0 x 108 cells/kg and PR
before allogeneic SCT.
Salama et al. evaluated 25 patients with MM from 15 BMT
centers who were treated with 1 to 4 DLIs after allogeneic BMT
from matched related (n  23), mismatched related (n  1), or
matched unrelated (n  1) donors [144]. Disease status at time
of allogeneic BMT was refractory (n 10), PR (n 13), relapse
(n  1), or CR (n  1). Nine patients achieved CR, 10 achieved
PR, 5 had no response, and 1 was not evaluable after transplan-
tation. Median T-cell dose for the ﬁrst DLI was 1.0 x 108
cells/kg in 18 patients with available data (range, 0.02-2.24 x 108
cells/kg). Nine patients received a second DLI at a median of 16
weeks after the ﬁrst. Median T-cell dose was 3.3 x 108 cells/kg
(n  7 with available data; range, 0.15-5.16 x 108 cells/kg). One
patient received a third and fourth DLI.
Thirteen of 25 patients (52%) developed acute GVHD
including 5 with grade III and 1 with grade IV. Eleven
patients developed chronic GVHD, including 5 with exten-
sive involvement. At a median follow-up of 19.5 months, 12
of 25 patients were alive, 2 in CR, and 10 with disease.
Thirteen patients died of progressive disease (n  10), infec-
tion (n  2), or GVHD (n  1). By univariate analysis,
patients given T-cell doses 1 x 108 cells/kg were more likely
to have both GVHD and disease response. Overall, 4 of 25
patients beneﬁted from DLI (disease response lasting at least
12 months), however, 3 had severe acute or extensive chronic
GVHD. Three additional patients possibly beneﬁted from
DLI (this is the ongoing disease response, but follow-up is
12 months), but 2 of them had signiﬁcant GVHD. Three
patients had a minimal beneﬁt from DLI (disease response
12 months) and 15 patients had no disease response to DLI
including 3 with signiﬁcant GVHD.
Alyea et al. examined 24 patients with MM treated with
CD6 T-cell depleted allogeneic BMT from matched sib-
ling donors followed by prophylactic CD4 DLI as a single
infusion given 6 to 9 months post-BMT in the absence of
GVHD and immunosuppressive therapy [145]. Patients re-
ceived a median of 3 prior chemotherapy regimens (range,
1-7); median time from diagnosis to BMT was 10 months.
Conditioning regimens were Cy plus TBI (1400 cGy; n  21)
or busulfan plus Cy (n  3). T-cell depletion was the only
method of GVHD prophylaxis.
All patients achieved neutrophil recovery at a median of
12 days (range, 10 to 17 days) and platelet recovery at a
median of 19 days (range, 16 to 28 days) after allogeneic
BMT. Day 100 TRM rate was 4%. Five patients (21%)
developed grade II to III acute GVHD after BMT. Seven of
14 patients who received DLI developed grade II to IV acute
GVHD or extensive chronic GVHD after DLI. At a median
follow-up of 2.3 years, the 2-year OS and PFS rates were 55%
(95% CI, 34%-76%) and 30% (95% CI, 10%-50%). Patients
in the T-cell depleted BMT plus DLI group were compared
with a cohort of 38 patients treated with T-cell depleted
allogeneic BMT without DLI. There was no signiﬁcant dif-
ference in 1- or 2-year OS or PFS between the 2 groups.
Badros et al. reported 16 patients with MM who received an
allogeneic PBSCT from an HLA-matched (n  14) or mis-
matched (n  2) sibling donor using a non-myeloablative con-
ditioning regimen (MEL 100 mg/m2) followed by 1 (n  5), 2
(n  4), or 3 (n  3) DLIs [146] (update of Badros et al. [132]).
Patients had received 1 (n  9) or 2 (n  7) prior autologous
transplants. At time of allogeneic PBSCT, 10 were in refractory
relapse, 4 were in PR, and 2 were in near CR (CR but with
positive immunoﬁxation). DLIs were given to 14 patients with
T. Hahn et al.
24
no evidence of GVHD to induce full chimerism (n  4) or to
treat residual disease (n  10).
One patient who failed to achieve neutrophil engraftment
after a second infusion of allogeneic PBSCs was given autolo-
gous back-up stem cells that achieved autologous engraftment
and a near CR. No patients died of TRM in the ﬁrst 100 days
post-PBSCT. Acute GVHD occurred in 10 patients, including
1 with grade IV; chronic GVHD occurred in 7 patients, includ-
ing 4 with extensive involvement. At a median follow-up of 12
months, 11 of 16 patients were alive, 5 in CR, 3 in near CR, and
4 in PR. Three patients died of GVHD and 2 of progressive
disease.
Second SCT for the Treatment of Relapse after a
Prior SCT
Tricot et al. studied 94 patients who relapsed after an
autologous transplantation and were treated with either stan-
dard-dose salvage therapy (n  53; VAD, EDAP, high-dose
dexamethasone, or other derivatives) or another transplantation
(31 autologous and 10 allogeneic) [147]. Seventy-one patients
had relapsed after 1 and 23 patients relapsed after 2 prior
autologous transplantations. Patients were offered standard sal-
vage chemotherapy if they had no cryopreserved BM or PB or
had rapidly progressing disease (plasmablastic transformation,
rapid increase in tumor mass, or hypercalcemia). Another trans-
plantation was performed if patients had adequate cryopreserved
BM or PB and no rapidly progressing disease. At a median
follow-up of 11 months after salvage therapy, patients who
received a transplant had a signiﬁcantly higher CR rate (22%
versus 2%; P  .002) and OS rate (at 18 months, 78% versus
41%; P  .009) than patients who received standard salvage
chemotherapy. By multivariate analysis, independent predictors
of prolonged OS were pre-salvage B2M 2.5 mg/L and relapse
12 months after the preceding transplantation.
Mehta et al. compared 42 patients treated with an allogeneic
SCT after a failed autologous SCT to 42 pair-matched controls
who were treated with a second autologous SCT as salvage
therapy [148]. Controls were matched for albumin, C-reactive
protein, creatinine, disease sensitivity, duration of standard ther-
apy prior to ﬁrst SCT, Ig isotype, karyotype, LDH, and re-
sponse to ﬁrst SCT. Patients given a second autologous SCT
were older, had a higher B2M, and a shorter interval between
the 2 SCTs than those given a second allogeneic SCT. Approx-
imately half the patients were offered a second transplantation
due to failure to achieve at least a PR to the ﬁrst, and the other
half experienced disease progression after their ﬁrst transplan-
tation.
There was no signiﬁcant difference between the second
allogeneic versus the autologous SCT groups with regard to CR
rate (41% versus 33%; P not signiﬁcant) or 3-year EFS rate
(20%  8% versus 25%  8%). Second autologous SCT pa-
tients had a signiﬁcantly higher 3-year OS rate (54% versus
29%; P  .01) and 3-year probability of disease progression
(72% versus 31%: P .03) compared with the allogeneic group.
A signiﬁcantly higher 1-year probability of TRM was demon-
strated in patients who received a second allogeneic SCT com-
pared with patients who received a second autologous transplant
(43% versus 10%; P  .0001).
Garban et al. studied 12 patients with persistent or relapsed
MM previously treated with at least VAD plus an autologous
SCT who were given a second transplant [149]. The patients,
who were not eligible for conventional allogeneic transplanta-
tion due to age or poor performance status, received PBSCT
(n  11) or BMT (n  1) from HLA-matched sibling donors
using a nonmyeloablative conditioning regimen consisting of
ﬂudarabine, anti-thymocyte globulin, and busulfan. Prior con-
ditioning for the autologous transplantation had beenMEL (140
mg/m2) plus TBI or MEL (200 mg/m2). Cyclosporine was given
for 45 to 90 days after non-myeloablative allogeneic SCT for
GVHD prophylaxis.
Four patients achieved CR, 7 achieved PR, and 1 progressed
after allogeneic SCT. All patients engrafted, no mucositis oc-
curred, no parenteral feeding was required, and some patients
did not require platelet transfusions. Three patients died before
day 100, one from progressive disease despite GVHD, one with
preexisting cardiopathy died from acute cardiac failure, and one
whose cause of death was not given. Six patients developed grade
II to IV acute GVHD, and 7 patients developed chronic GVHD
(including 2 with extensive involvement). Five patients devel-
oped systemic or localized cytomegalovirus (CMV) infection,
including one who died 5 months post-SCT from CMV en-
cephalitis.
Singhal et al. reported a study of 88 patients with MM who
underwent 1 (n  10) or 2 (n  78) prior autologous transplan-
tations and had no available cryopreserved stem cells for addi-
tional SCT [150]. Seventy-one patients received IFNa mainte-
nance therapy after the previous transplantation(s), which was
discontinued 2 to 3 months prior to subsequent SC collections.
Patients were mobilized with G-CSF (median dose 13.4 g/kg;
range, 4.8-24). A median of 3.03 x 106 CD34 cells/kg (range,
0.46-9.16) were collected by apheresis (median number of col-
lections, 5; range, 2-13). The time between preceding transplan-
tation and PBSC collections was a median of 29 months (range,
5-68 months). By multivariate analysis, patients with platelet
counts 200 x 109/L (P  .0001), no myelosuppressive chemo-
therapy between last SCT and collections (P .02), and with no
(n  17) or 6 months (n  15) of IFNa (P  .03) had
signiﬁcantly higher CD34 cell yields.
Mehta et al. studied 18 patients with MM with relapsed
disease after a median of 5 prior regimens (range, 4-10)
treated with an autologous PBSCT with cyclophosphamide
plus carboplatin plus etoposide (CCV) conditioning regimen
[151]. Fifteen patients had received a prior autologous trans-
plant, 2 patients had 2 prior autologous transplants, and 1
patient had received prior autologous and allogeneic trans-
plants. Four patients died from TRM on days –1, 0, 3, and 10
post-PBSCT. Causes of death were acute renal failure with
congestive heart failure, cardiac arrest, respiratory failure due
to ﬂuid overload, and multi-organ failure, respectively. Of the
remaining 14 patients, 1 achieved a CR, 1 a PR, 2 had 50%
reduction in tumor mass, and the remainder had no response
or progressive disease. Nine patients died of relapsed or
progressive disease at a median of 7 months post-PBSCT, 5
were alive (1 with stable PR and 4 with progressive disease) at
a median of 13 months post-PBSCT.
SCT ECONOMIC/COST-EFFECTIVENESS STUDIES
Lenhoff et al. performed a prospective, non-randomized,
population-based, multicenter study of 274 patients with MM
comparing autologous PBSCT with MEL conditioning and
IFNa maintenance with 274 historical controls pooled from 5
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randomized trials of conventional chemotherapy, as previ-
ously described [5]. Gulbrandsen et al. reported a companion
study that collected data on costs, resource consumption, and
health-related quality-of-life (HRQoL) at baseline and dur-
ing periodic follow-up of the prospective trial; the same
method had been used in one of the historical trials including
patients treated with MP for induction (n  70) [152]. In the
PBSCT group, 221 patients (78%) participated in the
HRQoL study, of whom 201 patients (73%) completed all
questionnaires. In the MP group, 66 patients (94%) partici-
pated and 61 patients (87%) completed all questionnaires.
Quality-adjusted life-years (QALYs) were calculated with the
assumption of a mean 1.5-year gain in survival at the cost of
a 6-month reduction in the HRQoL.
The PBSCT group had signiﬁcantly prolonged median
OS compared with the MP group (62 versus 44 months). In
the PBSCT group, resource consumption included medical
costs, hospital stay (including intensive care unit days), per-
sonnel costs (physicians and nurses), leukapheresis, and trans-
fusions, and involved a cost of $24,400 (all costs are in year
2000 United States [US] dollars). Indirect costs measuring
lost production (estimate of 104 days of lost unpaid employ-
ment per person) were estimated at $7,900, for a total societal
cost per PBSCT patient of $32,300. The cost-utility ratio for
PBSCT over MP was $27,000 per QALY, and by sensitivity
analysis ranged from $20,200 to $40,000 per QALY.
Uyl-de Groot et al. retrospectively calculated the treat-
ment costs of 26 patients with MM who received MEL (n 
11) or MEL plus G-CSF (n  7) compared with autologous
transplantation with G-CSF mobilized PBSC re-infused af-
ter MEL (n  8) [153]. Costs included hospital days (person-
nel, supplies, medical services, and overhead), diagnostics,
pharmacy, laboratory, insertion of central venous catheters,
and transfusions. The PBSCT group had signiﬁcantly lower
costs for hospital days (US $7,335 versus $16,747; P  .005),
antibiotics ($2,454 versus $6,476 ; P  .01), parenteral nu-
trition ($229 versus $2,148 ; P  .001), transfusions
($1,065 versus $2,762; P  .05), and total treatment costs
($17,908 versus $32,223; P  .005) compared with the MEL
/- G-CSF group. The PBSCT group had signiﬁcantly
higher costs for G-CSF ($5,293 versus $1,393: P  .01)
compared with the MEL /- G-CSF group. The article
does not state what calendar year the costs in US dollars
represent, although the article was submitted to the journal in
1993.
Henon et al. retrospectively compared the survival, qual-
ity of life, and therapy costs of 12 patients with MM stage III
treated with MEL as induction and mobilization, PBSC col-
lections, and autologous transplantation (group 1) with 10
patients with similar characteristics but treated with conven-
tional chemotherapy (group 2) with 15 patients with MM
stage II treated with conventional chemotherapy (group 3)
[154]. The conventional chemotherapy regimen consisted of
at least 6 cycles of either VAD or M2 (BCNU, eldisine, Cy,
and MEL); the conditioning regimen was MEL (140 mg/m2)
plus TBI. Group 1 patients did not receive any maintenance
therapy post-PBSCT; they were treated at time of relapse
with one of the conventional chemotherapy regimens listed
above or with subcutaneous IFNa plus pulse dexamethasone.
Group 2 patients surviving at 6 months post-induction ther-
apy received maintenance therapy with the regimen they did
not initially receive (VAD or M2). Group 3 patients were
treated with MP as maintenance therapy in case of disease
response and conventional chemotherapy in case of disease
progression.
The average total costs (all in 1993 US dollars) for each
group including all therapy as deﬁned above was signiﬁcantly
higher in group 1 ($56,700) versus group 2 ($46,555; P  .05)
versus group 3 ($37,430; P  .02). The average total costs of
therapy based on mean survival duration in group 1 was
signiﬁcantly lower ($350/wk) compared with group 2
($1,862/wk: P  .0001) but signiﬁcantly higher than group 3
($225/wk; P  .05). When these values were adjusted for
quality of life, group 1 cost $74/wk more than group 2 and
$966/wk more than group 3.
Duncan et al. performed a cost-minimization analysis of
51 patients with MM comparing autologous BMT (n  14)
versus PBSCT (n  37) [155]. All patients received induction
therapy with VAMP, C-VAMP, or verapamil, Cy, vincristine,
adriamycin, and methylprednisolone (VC-VAMP) followed
by MEL (200 mg/m2) and infusion of either BM or PBSC.
The PBSCT group had a signiﬁcantly faster time to neutro-
phil engraftment (16 versus 22 days; P  .0019) and time to
platelet recovery (19 versus 27 days; P  .0019), which re-
sulted in a shorter duration of intravenous antibiotics (12
versus 19 days; P  .0001), reduced number of platelet trans-
fusions (12 versus 31.5 units; P  .0005), and shorter hospital
length of stay (19 versus 27.5 days; P  .0001). The total cost
of PBSCT was 27.5% less than autologous BMT (actual costs
are stated in British pounds with no conversion to US dollars
and no calendar year indicated).
Jagannath et al. compared 91 patients with MM who
received a total of 118 transplants as outpatients with 160
patients with MM who received 218 transplants as inpatients
[156]. Patients treated as outpatients were younger, had a
higher percentage of CD34 cells in the apheresis product,
and were more likely to have a normal serum albumin level,
low B2M level, and chemotherapy-sensitive disease than in-
patients. There was no signiﬁcant difference in the hemato-
logic recovery between inpatients and outpatients. Twenty-
one percent of patients who underwent outpatient
transplantations required admission after transplantation for
nauseau, vomiting, diarrhea requiring parenteral alimentation
and/or severe mucositis requiring narcotic analgesics (28%),
bacteremia or pneumonia (28%), febrile neutropenia and
gastrointestinal toxicity (24%), persistent fever for more than
3 days (12%), or were admitted at the discretion of the
physician (8%). B2M 2.5 mg/L was the only signiﬁcant risk
factor for hospital admission in the outpatient transplant
group (58% versus 24%; P  .001). Median hospital length of
stay was 9 days for outpatients versus 15 days for inpatients
(P  .0001).
Total charge for the transplantation procedures included
physician, hospital, and clinic charges. A multivariate analysis
assessing age, gender, prior response to therapy, time from
diagnosis to ﬁrst transplantation, Ig isotype, disease stage,
number of CD34 cells infused, serum creatinine, albumin,
B2M, and LDH was performed to identify factors associated
with savings. Outpatient transplantation was the only factor
associated with savings. Total average adjusted charges were
$13,172 (1994 US dollars) lower for outpatients compared
with inpatients. Speciﬁcally, outpatients had lower hospital-
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ization charges (50% of overall savings), pharmacy charges
(42%), and pathology/laboratory charges (37%). Outpatients
had higher miscellaneous charges (-30% of overall sav-
ings) including housing and caregiver costs.
Bujit et al. calculated the treatment and follow-up costs in
a retrospective study of 29 patients with newly diagnosed MM
[157]. Costs included those for hospitalization, outpatient
visits, laboratory, pharmacy, pathology, imaging (X-rays,
computed tomography, etc.), apheresis, transfusions, inser-
tion of central venous catheters, personnel, supplies, medical
equipment, and overhead. All prices are stated in 1995 US
dollars. Each patient was scheduled to be treated and fol-
lowed in 8 phases (mean cost for each phase and number of
patients completing that phase): VAD or VAMP induction
($8,400; n  29), follow-up I ($425; n  29), MEL plus whole
blood rescue ($11,000; n  29), follow-up II ($1,825; n  26;
3 patients died during this phase), PBSC collections ($9,350;
n  21), follow-up III ($1,250; n  17; 1 patient died during
this phase), autologous PBSCT with busulfan plus Cy con-
ditioning ($15,125; n  15; 2 patients died during this phase),
and follow-up IV until 3 months post-hospital discharge after
PBSCT ($2,400; n  13). The total mean costs of treatment
and follow-up for the 13 patients who completed the program
as scheduled was $44,800 and for the 16 who did not com-
plete the entire program or who required additional therapy
was $57,025.
Trippoli et al. conducted a meta-analysis of 5 clinical
trials published between 1993 and 1996 with at least 100
patients with newly diagnosed untreated MM per treatment
arm, and determined the cost-effectiveness ratio [158]. The
trials included 4 comparing MP /- IFNa and one comparing
autologous BMT versus conventional chemotherapy. Survival
data were abstracted and pooled (where more than 1 trial
evaluated the treatment) from the published trial data and
used to calculate the mean lifetime survival (MLS) for each
therapy. Costs also were abstracted from the published liter-
ature of autologous transplantation and estimated at $60,000
(1995 US$) per patient, however a sensitivity analysis of
the transplantation cost data used the range of $20,000
to $120,000 as the most extreme published values. Four of
the clinical trials published cost data on MP as induction
therapy, which averaged $2,700 per patient; no sensitivity
analysis was performed for MP because of the high precision
of these data.
The pooled MLS values for the MP versus MP plus IFNa
were not signiﬁcantly different (3.47 versus 3.74 years; P 
.05). Autologous BMT had a signiﬁcantly longer survival than
the MP group (MLS 7.28 years; P  .05). The cost-
effectiveness ratio was calculated by dividing the difference in
costs between MP and BMT by the difference in life years
gained (LYG) per patient. Using the $60,000 estimate for
BMT, the cost per LYG (cost-effectiveness ratio [CER]) was
$25,710 and ranged from $7,773 to $52,616 by the sensitivity
analysis.
Sampson et al. identiﬁed from the literature 1 random-
ized controlled trial and 2 case series of high-dose therapy
with autologous SCT versus conventional-dose chemother-
apy as ﬁrst-line treatment of MM [159]. Examined outcomes
were LYG and event-free LYG. Cost estimates for SCT were
based on out-of-area treatment costs for Central Shefﬁeld
University Hospitals and included costs for mobilization,
stem cell harvest, 3-week inpatient hospital stay, outpatient
follow-up, and pharmacy costs. The overall average treatment
cost for SCT was £12,460 per patient. Cost estimates for
conventional chemotherapy were based on the pharmacy
costs of 6 to 9 courses of ABCM (Adriamycin, BCNU, cy-
clophosphamide, and MEL) and additional outpatient visit
costs, yielding an average treatment cost of £1,980 per pa-
tient. The randomized trial data resulted in a mean 5-year
survival beneﬁt of 0.7 LYG for SCT patients, an additional
0.7 event-free LYG for SCT patients, and a CER of £14,970
per LYG. A sensitivity analysis using the case series data
with information on 10-year survival rates determined
the survival beneﬁt to be 1.7 LYG and a CER of £6,160 per
LYG. Fitting a mathematical Weibull curve to the survival
data points yielded a 10-year survival beneﬁt of 2.3 LYG, a
CER of £4,553 per LYG, and a 20-year survival beneﬁt of 3.8
LYG.
RESPONSE CRITERIA (METHODS TO DETECT MINIMUM
RESIDUAL DISEASE)
Various techniques to measure biochemical or molecular
tumor markers have been examined for their ability to detect
minimum residual disease (MRD) in apheresis products, BM
harvests, or in patients with MM pretransplantion and post-
transplantation, and to predict prognosis. The most widely
used method has been real-time polymerase chain reaction
(PCR) to detect markers from the rearrangement of the
immunoglobulin heavy chain (IgH) genes to idiotype speciﬁc
sequences.
Two studies have reported that patients with MM whose
apheresis products test positive for clonogenic IgH by PCR
have signiﬁcantly shorter PFS and OS [160-162]. Three stud-
ies have reported that there is no prognostic signiﬁcance of
detection of MRD by PCR [163-165]. Two studies demon-
strated the percentage of tumor cells was signiﬁcantly higher
in BM harvests than in PBSC collections [166,167], whereas
1 study showed no difference in the percentage of tumor cells
or CD34 cells in leukapheresis products from the ﬁrst
versus second day of collection [168]. Two studies demon-
strated that CD34 selection of PBSC products signiﬁcantly
reduces the number of clonal cells by 2.15 logs [169] and by
up to 3 logs [170], which corresponds to a reduction in the
total quantity of tumor cells re-infused of 99.3% [169]. One
study compared the detection of MRD by PCR versus
immunoﬁxation versus electrophoresis and determined that
immunoﬁxation was the only method that correlated with
prognosis [171]. Another study noted that positive PCR
detection of MRD signiﬁcantly correlated with serum
B2M level, but had only a marginal correlation with progno-
sis [172]. One study concluded there is no correlation be-
tween circulating clonal B cells and CD19 cell count, and
that the PB clonal cells were reduced after induction therapy
but remained stable before and after PBSCT [173]. An addi-
tional study reported that clonotypic PBSCs are CD19 B
cells, and that the level of clonotypic cells decreases but
persists after treatment [174]. Two studies reported that
patients who received allogeneic transplants had a sig-
niﬁcantly higher rate of molecular CR determined by
prospective PCR monitoring of MRD than patients who
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received autologous transplants [175-177]. One study of al-
logeneic SCT patients demonstrated that 9 of 12 patients in
clinical CR were also in molecular CR at a median of 6
months after transplantation [178]. One study provided a
multicenter consensus strategy for detection of MRD and
concluded that PCR is a more reproducible method than
limiting dilution assays [179]. One study described the use of
family-speciﬁc consensus probes instead of patient-speciﬁc
idiotype sequences with real-time PCR for detection of
MRD as a faster, reproducible, and less expensive method
[180].
Other strategies have been investigated to detect MRD.
Two studies noted a reduction in BM microvessel density
(angiogenesis) after SCT, one associated the reduction with
response to SCT and PFS [181] whereas the other found it
was not prognostic of response to SCT [182]. One study
determined that plasma cell morphology was prognostic of
response to SCT and OS [183]. One study used an immuno-
ﬂuorescence technique to detect monoclonal plasma cells in
PBSC apheresis products [184]. Patients who had relapsed
disease at the time of leukapheresis had a signiﬁcantly higher
mean number of plasma cells and PB plasma cell labeling
index in their products than patients collected in the plateau
phase. One study compared 3 methods for estimating the BM
plasma cell percentage: BM aspirate, core biopsy, and plasma
cell labeling index [185]. There was a signiﬁcant correlation
between the 3 methods, and the highest estimate of BM
plasma cell percentage as determined by the 3 methods was a
signiﬁcant predictor of CR, PFS, and OS.
One study assessed bone resorption by measuring urinary
free pyridinoline (fPyr) and deoxypyridinoline (fDPyr), and as-
sessed bone formation by measuring the serum concentrations
of procollagen 1 extension peptide (P1CP) and bone-speciﬁc
alkaline phosphatase (BSAP) [186]. Patients with elevated levels
of fPyr, fDPyr, P1CP, and/or BSAP at the time of SCT had a
normalization of their levels within a few months post-SCT,
indicating a normalization of the abnormal bone turnover com-
mon in MM.
Several studies have used ﬂow cytometry to quantitate ma-
lignant plasma cells or other markers. One used ﬂow cytometry
to quantitate and compare the number of malignant plasma cells
in patients treated with conventional chemotherapy versus au-
tologous PBSCT [187]. Patients treated with autologous PB-
SCT had a signiﬁcantly reduced number of malignant plasma
cells and patients with 30% normal plasma cells after treat-
ment had signiﬁcantly prolonged PFS (60 versus 34 months;
P  .02). One study described the feasibility of using ﬂow
cytometry to measure myeloma-related antigens (B-B4 and
CD38) as a method to detect aneuploid plasma cells in PBSC
collections [188]. Another study used ﬂow cytometry to detect
plasma cells in apheresis products and demonstrated that imma-
ture plasma cells are polyclonal, whereas mature plasma cells are
monoclonal [189].
Two studies have evaluated interphase ﬂuorescence in
situ hybridization (FISH) as a method to detect MRD. In one
study, interphase FISH was able to detect abnormal plasma
cells in the BM of 12/14 patients who had achieved a clinical
CR after PBSCT (n  11) or high-dose MEL without stem
cell support (n  3) [190]. In the other study, interphase
FISH detected aneuploid cells in BM harvests that were
prognostic of signiﬁcantly shorter DFS (12 versus 23 months;
P  .009) [191].
One study used ﬂow cytometry to sort PB samples into
CD19, CD19-, and CD20 fractions [192]. PCR was used to
quantitate the number of CD19 tumor cells in MM patients in
remission post-PBSCT and found it to be similar to patients
treated with standard-dose chemotherapy (VAD plus idarubi-
cin), however, tumor cells detected in the CD19- fraction were
signiﬁcantly reduced in patients in remission post-PBSCT. In
MM patients with progressive disease post-PBSCT, the number
of tumor cells in the CD19 and CD19- fractions was signiﬁ-
cantly higher than in remission patients post-PBSCT.
One study explored ﬂow cytometry immunophenotyping
using a panel of 21 monoclonal antibodies in a two-step gated
procedure with DNA ploidy studies to detect MRD [193]. In
BM samples from 61 patients with untreated newly diagnosed
MM, 87% had an abnormal phenotype, 62% demonstrated
DNA aneuploidy, and 95% had one or both techniques detect-
ing abnormal plasma cells. Three months after autologous SCT,
29 PBSC and 19 BM samples were obtained. Abnormal plasma
cells were detected in 44% of PBSC collections and 61% of BM
samples.
FUTURE DIRECTIONS
Ongoing Studies
Several studies have been published in abstract form only,
were recently completed, or are currently accruing patients
but address critical issues that will affect the treatment rec-
ommendations made above. Maloney et al. described a feasi-
bility trial of 32 patients treated with an autologous PBSCT
followed by an allogeneic PBSCT from an HLA-identical
sibling with a non-myeloablative conditioning regimen [194].
Attal et al. reported a multicenter randomized phase III trial
of single versus tandem autologous PBSCT in 399 patients
[195]. Segeren et al. conducted a multicenter randomized
phase III trial of VAD followed by MEL (140 mg/m2) without
stem cell rescue versus VAD followed by Cy plus TBI and
autologous PBSCT in 373 patients with previously untreated
MM [196]. Blade et al. performed a multicenter randomized
phase III trial comparing intensiﬁcation therapy with 8 cycles
of alternating BVMCP/VBAD versus autologous PBSCT
with MEL (140 mg/m2) plus TBI or MEL (200 mg/m2)
in 216 patients with MM treated with the same induction
regimen [197]. Kropff et al. reported a randomized phase III
trial of a standard (MEL 200 mg/m2) versus intensive
(MEL 200 mg/m2 plus Cy 120 mg/kg plus idarubicin
42 mg/m2) conditioning regimen for autologous PBSCT in
116 patients [198]. The ﬁnal analyses of these trials in
manuscript form with mature data will provide additional
evidence that may change or add to the treatment recommen-
dations.
Other studies that were recently closed or are still accruing
patients include the following: (1) an SWOG/Eastern
Cooperative Oncology Group/Cancer and Leukemia Group
B–sponsored multicenter phase III randomized trial of VBMCP
versus autologous PBSCT with MEL plus TBI conditioning as
intensiﬁcation therapy in patients with MM with stable or re-
sponding disease after induction therapy with VAD; patients
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with at least a 75% cytoreduction after intensiﬁcation undergo a
second randomization of maintenance therapy with IFNa versus
observation; and (2) an industry-sponsored, National Cancer
Institute sponsored multicenter phase III randomized trial of
MEL with or without a Holmium radiolabelled antibody as
conditioning for autologous PBSCT; this study was closed due
to late toxicity observed in the phase I/II patients and is being
revised for further accrual.
Areas of Needed Research
After reviewing the evidence and highlighting the studies
that are in progress, the panel recommends as the most im-
portant area of needed research the following: studies of
post-response therapy to improve the quality of the response
and extend survival. This includes studies of maintenance ther-
apy of patients treated with autologous SCT, ie, posttrans-
plantation maintenance studies comparing IFNa versus pred-
nisone or thalidomide or its derivatives. Because there is
no plateau in the survival curves post-autologous SCT for
MM, this is the area most in need of improvement by further
study.
DISCUSSION
In addition to the topics covered, we reviewed the evidence
for PBSC mobilization regimens and timing of PBSC collec-
tions for autologous and allogeneic SCT. The panel concluded
that there was not adequate evidence nor was this topic imme-
diately relevant to the evaluation of outcomes after PBSCT,
therefore, these sections were not included. We examined the
evidence for vaccine therapy post-autologous SCT. These stud-
ies included too few patients to make a meaningful recommen-
dation regarding this novel approach and also were excluded.
The panel noted that although expert opinion has set an upper
age limit of 70 years for autologous SCT, the decision for
transplantation in the elderly population should be made on a
case-by-case basis.
The authors recommend methodology standardization, in-
cluding study design, analytical tests, and response criteria. Mul-
ticenter randomized phase III comparative trials with large en-
rollments and high statistical power are required in the US to
advance the ﬁeld more constructively than single institution
phase II trials with one treatment arm. A standard set of re-
sponse criteria, such as the International Bone Marrow Trans-
plant Registry (IBMTR) MM response criteria, should be used
for documentation of MM therapy responses. The expert panel
also noted in the course of this review that the publication of
preliminary analyses is often premature because a minimum of 3
to 5 years of follow-up is required before the survival curves start
to separate due to the effect of posttransplantation salvage ther-
apies. We advocate prompt reporting of mature data in full
manuscript format. Abstracts do not adequately convey the full
details of a clinical trial to meet evidence-based criteria for
inclusion in systematic reviews, nor for making a true assessment
of the widespread applicability or impact of the treatment out-
side the scope of the trial.
The treatment recommendations of this panel are based on
the results of well-planned, scientiﬁcally sound, peer-reviewed
clinical trials. All of today’s current therapy for cancer is the
result of the randomized clinical trial process. It is currently
estimated that less than 5% of adults eligible to participate in
cancer clinical trials actually enroll in a trial. The authors ac-
knowledge the importance of third party payers in removing one
barrier to participation in clinical trials by providing insurance
coverage for the routine costs of care for patients enrolled in
cancer clinical trials. We urge all carriers to extend beneﬁts for
participation in cancer clinical trials that is at least consistent
with the scope of coverage deﬁned by the Center for Medicare
and Medicaid Services in the September 19, 2000 regulations to
answer the critical treatment questions, not only for MM, but
also for other malignant diseases.
LIMITATIONS OF THIS EVIDENCE-BASED LITERATURE
REVIEW
There are limitations to any evidence-based review of the
published literature. The criteria for this review included reli-
ance only on published data, speciﬁcally peer-reviewed articles
published since 1980. Unpublished data, which were not in-
cluded in the review, usually represent “negative” ﬁndings and
usually do not undergo peer review. We also excluded data
published only in abstract form because they are usually not
peer-reviewed and are presented in an abbreviated format.
Another limitation of this review is its reliance on published
data rather than individual patient data. The stated goal of this
review was to present evidence for making recommendations
regarding the role of SCT in the therapy of MM. Time and
ﬁnancial constraints made it impractical to obtain data on indi-
vidual patients from the large number of clinical trials included
in this review. Although it was not the objective of this review to
perform an extensive meta-analysis of individual patient data,
such an analysis is warranted to further clarify the results of
studies and address unanswered questions.
FUTURE INITIATIVES
This comprehensive, systematic review of the available ev-
idence for the role of cytotoxic therapy with hematopoietic SCT
in the therapy of MM is the second in a series of sequential
articles sponsored by the American Society for Blood and Mar-
row Transplantation. Each review will summarize the evidence
regarding the role of cytotoxic therapy with SCT in the treat-
ment of a speciﬁc disease using deﬁned methodology and grad-
ing criteria. The next review will address the role of SCT in the
therapy of acute lymphoblastic leukemia (ALL).
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Appendix A. Glossary of Terms
ABCM Adriamycin, BCNU, cyclophosphamide, and melphalan
ALL Acute lymphoblastic leukemia
ANC Absolute neutrophil count
B2M Beta2-microglobulin
BCNU Carmustine
BM Bone marrow
BMT Bone marrow transplantation
BSAP Bone-specific alkaline phosphatase
BVAP Carmustine (BCNU), vincristine, Adriamycin, and prednisone
BVAPP Carmustine (BCNU), vincristine, Adriamycin, and prednisone plus alternate day prednisone between chemotherapy cycles
CALGB Cancer and Leukemia Group B
CCV Cyclophosphamide, carboplatin, and etoposide
CER Cost-effectiveness ratio
CHOP (intensified) Cyclophosphamide, Adriamycin, vincristine, and prednisone
CI Confidence interval
CM Cyclophosphamide and melphalan
CMV Cytomegalovirus
CR Complete response
CRP C-reactive protein
C-VAMP Cyclophosphamide, vincristine, Adriamycin, and methylprednisolone
CVB Cyclophosphamide, etoposide, and carmustine (BCNU)
Cy Cyclophosphamide
d-TEC Dexamethasone, paclitaxel, Etoposide, and cyclophosphamide
DAV Dexamethasone (orally days 1-4), Adriamycin (intravenous day 1), and vincristine (intravenous day 1)
DCs Dendritic cells
DFS Disease-free survival
DLIs Donor lymphocyte infusions
EBMT European Group for Blood and Marrow Transplantation
ECOG Eastern Cooperative Oncology Group
EDAP Etoposide, dexamethasone, cytosine arabinoside, and cisplatinum
EFS Event-free survival
fDPyr Urinary free deoxypyridinoline
FISH Fluorescence in situ hybridization
FFP Free(dom) from progression
fPyr Urinary free pyridinoline
G-CSF Granulocyte–colony stimulating factor
GM-CSF Granulocyte-macrophage–colony stimulating factor
GVHD Graft-versus-host disease
HDS High-dose sequential
HLA Human Leukocyte Antigen
HRQoL Health-related quality-of-life
IDM Intermediate-dose melphalan
IFNa Interferon alpha
Ig Immunoglobulin
LCR Plasma cell light chain ratio
LDH Lactate dehydrogenase
LYG Life years gained
M2 BCNU, eldisine, cyclophosphamide, and melphalan
MDS Myelodysplastic syndrome
MEL Melphalan
MLS Mean lifetime survival
MM Multiple myeloma
MP Melphalan and prednisone
MPC Monoclonal plasma cells
MRD Minimum residual disease
NMSG Nordic Myeloma Study Group
OS Overall survival
P1CP Procollagen 1 extension peptide
PBSC Peripheral blood stem cell
PBSCT Peripheral blood stem cell transplantation
PCR Polymerase chain reaction
PFS Progression-free survival
PR Partial response
QALYs Quality adjusted life years
RFS Relapse-free survival
RSV Respiratory syncytial virus
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